FORM PTO-1390 (REV 10-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C.371	**NCI-108US**
	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/030350

INTERNATIONAL APPLICATION	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB00/02623	**07 July 2000 (07.07.00)**	**09 July 1999 (09.07.99)**

TITLE OF INVENTION

COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

APPLICANT(S) FOR DO/EO/US

Anne CLARK, *et al.*

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C.371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☒ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C 371(c)(2))
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). **(unexecuted) (5 Sheets);**
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included
13. ☒ A FIRST preliminary amendment **(4 sheets) (along with version of markings to show changes (3 sheets));**
    ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: **Transmittal Letter (2 sheets in duplicate); International Published Application W/O 01/03680 A2 (without International Search Report) (62 sheets); Invitation to Pay Additional Fees (with Partial International Search Report) (12 sheets); Certificate of First Class Mailing (1 sheet); and Return Postcard.**

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NO.
10/030350	PCT/GB00/02623	NCI-108US

17. ☒ The following fees are submitted:	CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) .(a/o November 1, 2000):		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....**$1000**		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **$890**		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.455(a)(2)) paid to USPTO **$710**		
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....**$690**		
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....**$100**		
ENTER APPROPRIATE BASIC FEE AMOUNT =	$890.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$130.00	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	**34**-20 =	**14**	X **$18.00**	$252.00	
Independent claims	**6**-3 =	**3**	X **$84.00**	$252.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ **270.00**	$	
TOTAL OF ABOVE CALCULATIONS =				$1524.00	
☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.				$	
SUBTOTAL =				$	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +				$	
TOTAL NATIONAL FEE =				$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$	
TOTAL FEES ENCLOSED =				$1524.00	
				Amount to be: refunded	$
				charged	$

a. ☐ Checks in the amount of $_____ to cover the above fees are enclosed.

b. ☒ Please charge my Deposit Account No. **12-0080** in the amount of $ **1524.00** to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **12-0080**. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Elizabeth A. Hanley, Esq.
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
United States of America
(617)227-7400
Date: 07 January 2002

SIGNATURE

Giulio A. DeConti Jr.
NAME

31,503
REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: **Anne CLARK, *et al.***

International Application No.: **PCT/GB00/02623**

International Filing Date: **7 July 2000**

U.S. Serial No.: **10/030,350**

Filed: **January 7, 2002**

For: ***COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION***

Attorney Docket No.: **NCI-108US**

Group Art Unit: Unassigned

Examiner: Unassigned

BOX PCT
Commissioner for Patents
Washington, D.C. 20231

CERTIFICATION UNDER 37 C.F.R. § 1.10

Date of Deposit: November 8, 2002 Mailing Label Number: EL 931 679 137 US

I hereby certify that paper or fee as enclosed are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 and addressed to Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Larry Taylor
Name of Person Mailing Paper

Signature of Person Mailing Paper

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

Dear Sir:

Responsive to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office dated April 8, 2002, Applicants' agent submits herewith six *executed* Declarations, Petitions and Powers of Attorney for the above-identified patent

application. A Request for a Five-Month Extension of Time is also filed herewith. A copy of the Formalities Letter is also enclosed.

The Commissioner is hereby authorized to charge payment of any fees under 37 C.F.R. 1.16 and 1.17 during the pendency of this application or credit any overpayment to Deposit Account No. 12-0080.

Please charge any underpayments or credit any overpayments associated with this communication to our Deposit Account No. 12-0080. A duplicate of this letter is enclosed.

Respectfully submitted,

Theodore R. West
Registration No. 47,202
Agent for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: November 8, 2002

11/14/2002 SNAJARRO 00000108 120080 10030350
01 FC:1255 1960.00 CH

IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)
(National Phase of International App.: PCT/GB00/02623, W/O 01/03680 A2)

In re the
application of: **Anne CLARK, *et al.***

International Application No.: **PCT/GB00/02623**

International Filing Date: **7 July 2000**

U.S. Serial No.: **Not Yet Assigned**

Filed: **Herewith**

For: **COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION**

Attorney Docket No.: **NCI-108US**

BOX PCT
Commissioner for Patents
Washington, D.C. 20231

Certification Under 37 CFR 1.10

I hereby certify that the attached:

Transmittal Letter (2 sheets in duplicate); Preliminary Amendment (4 sheets (along with version of markings to show changes (3 sheets)); Unexecuted Declaration, Petition and Power of Attorney (5 sheets); International Published Application W/O 01/03680 A2 (without International Search Report) (62 sheets); Invitation to Pay Additional Fees (With Partial International Search Report) (12 sheets); Certificate of Express Mailing (1 sheet); and Return Postcard are being deposited by me with the United States Postal Service "Express Mail Post Office to Addressee" service, Mailing Label No. **EL 892 219 542 US**, under 37 CFR 1.10 on the date indicated below and is addressed to the Box PCT, Commissioner for Patents, Washington, D.C. 20231.

Date: 07 January 2002

Name: Viriato G. Cardoso Signature: Viriato G Cardoso

NCI-108US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the
application of: **Anne CLARK, *et al.***

International Application No.: **PCT/GB00/02623**

International Filing Date: **7 July 2000**

U.S. Serial No.: **Not Yet Assigned**

Filed: **Herewith**

For: **COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION**

Attorney Docket No.: **NCI-108US**

Group Art Unit: Unassigned

Examiner: Unassigned

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

CERTIFICATION UNDER 37 C.F.R. § 1.10

Date of Deposit: 07 January 2002 Mailing Label Number: EL 892 219 542 US

I hereby certify that paper or fee as enclosed are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 and addressed to Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Viriato G. Cardoso
Name of Person Mailing Paper

Signature of Person Mailing Paper

PRELIMINARY AMENDMENT

Please amend the application as follows:

In the Specification:

At page 1, add the following new paragraph before the first paragraph:

Related Applications

This application is a national phase application pursuant to 35 U.S.C. § 371 *et seq.* based on international application number PCT/GB00/02623, filed July 7, 2000, which claims priority to GB 9916214.1 and US 60/142,907 both filed on July 9, 1999, and GB 9916315.6 and US 60/142,953 both filed on July 12, 1999.

In the Claims:

Please cancel claims 21, 25 – 26, 28 – 31, 37 – 40, 42, 45, 48 – 52 without waiver or prejudice.

Please amend claim 24 as follows:

24. Process according to claim 22 in which the cells are cultured in the presence of the inhibitor.

Please amend claim 27 as follows:

27. Process according to claim 22 wherein the inhibitor is (i) 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid; (ii) DL-2-amino-5-phosphovaleric acid; (iii) 1,2,3,4-tetrahydroisoquinoline; (iv) cyclohexylsulfamic acid; (v) O-phospho-L-serine; (vi) hexafluoroglutaric acid; (vii) 8-methoxyquinoline-5-sulfonic acid; (viii) 4-phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine; (ix) 3-amino-2-hydroxy-1-propanesulfonic acid; or (x) 3-dimethylamino-1-propanesulfonic acid; or a salt thereof.

Please amend claim 32 as follows:

32. A culture medium or a culture medium pre-mix which comprises an inhibitor or compound as defined in claim 27.

Please amend claim 35 as follows:

35. *Ex vivo* cells prepared by a process according to claim 22.

Please amend claim 36 as follows:

36. *Ex vivo* cells according to claim 35 wherein said cells are in a preparation that comprises an inhibitor or compound selected from (i) 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid; (ii) DL-2-amino-5-phosphovaleric acid; (iii) 1,2,3,4-tetrahydroisoquinoline; (iv) cyclohexylsulfamic acid; (v) O-phospho-L-serine; (vi) hexafluoroglutaric acid; (vii) 8-methoxyquinoline-5-sulfonic acid; (viii) 4-phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine; (ix) 3-amino-2-hydroxy-1-propanesulfonic acid; or (x) 3-dimethylamino-1-propanesulfonic acid; or a salt thereof.

Please amend claim 41 as follows:

41. A pharmaceutical composition comprising a cell according to claim 35 and a pharmaceutically acceptable carrier or diluent.

Please amend claim 43 as follows:

43. A vessel for containing a culture of cells, which vessel is coated with an inhibitor or compound as defined in claim 2.

Please amend claim 44 as follows:

44. A kit for culturing cells comprising a culture medium or culture medium pre-mix as defined in claim 32.

Please amend claim 46 as follows:

46. Method of identifying an inhibitor that can be used to prepare cells for transplantation in a process according to claim 22, comprising contacting a candidate substance with a mammalian cell and determining whether the candidate substance inhibits the formation of fibrils or causes the breakdown of fibrils, (i) the inhibition of formation of fibrils or (ii) the breakdown of fibrils, indication that the substance is an inhibitor that can be used in said process.

Please amend claim 47 as follows:

47. Method of identifying an inhibitor that can be used to prepare cells for transplantation in a process according to claim 22, comprising contacting a candidate substance with a protein capable of forming fibrils, or with a fibril, and determining whether the substance inhibits the formation of the protein into a fibril, or whether the substance causes the breakdown of the fibril, (i) inhibition of fibril formation or, (ii) the breakdown of fibrils, indicating that the substance can be used in said process.

Pursuant to 37 C.F.R. § 1.121(c)(1)(ii), a marked up version of the specification and claims showing the changes made appear as Appendices to this Preliminary Amendment.

REMARKS

The present amendment is entered in compliance with 37 C.F.R. § 1.78 and to more succinctly claim the invention disclosed herein. Cancellation or amendment of claims should not be construed as a waiver, and applicants reserve the right to pursue claims to subject matter of claims cancelled or amended herein in future continuing applications. No new matter has been added.

Respectfully submitted,



Giulio A. DeConti, Jr., Esq.
Registration No. 31,503
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: 07 January 2002

Appendix A: marked up versions of amendments showing the changes made

Related Applications

This application is a national phase application pursuant to 35 U.S.C. § 371 *et seq.* based on international application number PCT/GB00/02623, filed July 7, 2000, which claims priority to GB 9916214.1 and US 60/142,907 both filed on July 9, 1999, and GB 9916315.6 and US 60/142,953 both filed on July 12, 1999.

Appendix B: marked up version of the claims showing the changes made

24. (Amended) Process according to claim 22 [or claim 23] in which the cells are cultured in the presence of the inhibitor.

27. (Amended) Process according to [any one of] claim[s] 22 [to 24] wherein the inhibitor is
(i) 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid;
[FIGURE]
(ii) DL-2-amino-5-phosphovaleric acid;
[FIGURE]
(iii) 1,2,3,4-tetrahydroisoquinoline;
[FIGURE]
(iv) cyclohexylsulfamic acid;
[FIGURE]
(v) O-phospho-L-serine;
[FIGURE]
(vi) hexafluoroglutaric acid;
[FIGURE]
(vii) 8-methoxyquinoline-5-sulfonic acid;
[FIGURE]
(viii) 4-phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine;
[FIGURE]
(ix) 3-amino-2-hydroxy-1-propanesulfonic acid;
[FIGURE]
or
(x) 3-dimethylamino-1-propanesulfonic acid
[FIGURE];
or a salt thereof.

32. (Amended) A culture medium or a culture medium pre-mix which comprises an inhibitor or compound as defined in [any one of] claim[s] [2, 4, 22 or] 27.

35. (Amended) *Ex vivo* cells prepared by a process according to [any one of] claim[s] 22 [to 31].

36. (Amended) *Ex vivo* cells according to claim 35 wherein said cells are in a preparation that comprises an inhibitor or compound [as defined in any one of claims 2, 4, 27 or 32] selected from (i) 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid; (ii) DL-2-amino-5-phosphovaleric acid; (iii) 1,2,3,4-tetrahydroisoquinoline; (iv) cyclohexylsulfamic acid; (v) O-phospho-L-serine; (vi) hexafluoroglutaric acid; (vii) 8-methoxyquinoline-5-sulfonic acid; (viii) 4-phenyl-1-(3'-sulfopropyl)-1,2,3,6-

tetrahydropyridine; (ix) 3-amino-2-hydroxy-1-propanesulfonic acid; or (x) 3-dimethylamino-1-propanesulfonic acid; or a salt thereof.

41. (Amended) A pharmaceutical composition comprising a cell according to claim 35 [, 36 or 37] and a pharmaceutically acceptable carrier or diluent.

43. (Amended) A vessel for containing a culture of cells, which vessel is coated with an inhibitor or compound as defined in [any one of] claim[s] 2 [4, 22 or 27].

44. (Amended) A kit for culturing cells comprising a culture medium or culture medium pre-mix as defined in claim 32 [or a vessel as defined in claum 43].

46. (Amended) Method of identifying an inhibitor that can be used to prepare cells for transplantation in a process according to claim 22 [or 23], comprising contacting a candidate substance with a mammalian cell and determining whether the candidate substance inhibits the formation of fibrils or causes the breakdown of fibrils, (i) the inhibition of formation of fibrils or (ii) the breakdown of fibrils, indication that the substance is an inhibitor that can be used in said process.

47. (Amended) Method of identifying an inhibitor that can be used to prepare cells for transplantation in a process according to claim 22 [or 23], comprising contacting a candidate substance with a protein capable of forming fibrils, or with a fibril, and determining whether the substance inhibits the formation of the protein into a fibril, or whether the substance causes the breakdown of the fibril, (i) inhibition of fibril formation or, (ii) the breakdown of fibrils, indicating that the substance can be used in said process.

COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

Field of the invention

The invention relates to compounds for inhibiting amyloid deposits *in vivo*, cells for transplantation, a process for preparing the cells and a medium for culturing the cells. In particular the invention relates to the inhibition of islet amyloid polypeptide (IAPP) deposition *in vivo* and a process for the preparation of islet cells for transplantation into patients with diabetes.

Background to the invention

Amyloidosis refers to a pathological condition characterized by the presence of amyloid. Amyloid is a generic term referring to a group of diverse but specific intra- and extracellular protein deposits which are associated with a number of different diseases. The protein deposits comprise largely insoluble fibrillar material. The deposition of normally soluble proteins in this insoluble form is believed to lead to tissue malfunction and cell death.

Though diverse in their occurrence, all amyloid deposits have common morphological properties, including that they stain with specific dyes (e.g. Congo red), and have a characteristic birefringent appearance (sometimes characterized as "red-green") in polarized light after staining. They also share common ultrastructural features and common x-ray diffraction and infrared spectra. At least some of the protein in the deposits is in the form of fibrils. Many different proteins are known to form fibrils. Such fibrils consist of long cylindrical structures in which the proteins comprise β-sheets that propagate in the direction of the fibril twisting around each other.

Amyloidosis can be classified clinically as primary, secondary, familial and/or isolated. Isolated forms of amyloidosis are those that tend to involve a single organ system compared to systemic amyloidosis involving many organs and tissues. Different amyloids are characterized by the type of protein present in the deposit. For example, neurodegenerative diseases such as scrapie, bovine spongiform

encephalitis, Creutzfeldt-Jakob disease and the like are characterized by the appearance and accumulation of a protease-resistant form of a prion protein (referred to as AScr or PrP-27) in the central nervous system Similarly, Alzheimer's disease, another neurodegenerative disorder, is characterized by congophilic angiopathy and neuritic plaques which have the characteristics of amyloid In this localised form of amyloid the plaque and blood vessel amyloid is formed by the Alzheimer beta protein. Other diseases, such as complications of long-term hemodialysis and sequelae of long-standing inflammation or plasma cell dyscrasias are characterized by the accumulation of amyloid systemically In each of these cases, a different amyloidogenic protein is involved in amyloid deposition.

Islet amyloid polypeptide (IAPP), also known as "amylin", is known to be capable of forming fibrils which are deposited in the pancreatic islets of patients with Type II diabetes, forming deposits Once these amyloid deposits have formed, there is no known therapy or treatment which significantly prevents, reduces or clears the deposits *in situ*. The inventors have now identified compounds for this purpose

With regard to another aspect of the invention, diseases caused by the death or malfunctioning of a particular type or types of cells can be treated by transplanting into the patient healthy cells of the relevant type of cell. Often these cells are cultured *in vitro* prior to transplantation to increase their numbers, to allow them to recover after the isolation procedure or to reduce their immunogenicity. However, in many instances the transplants are unsuccessful, due to the death of the transplanted cells. The inventors have now also found that culturing of cells can lead to the formation of fibrils from endogenous proteins. Such fibrils are likely to continue to grow after the cells are transplanted and cause death or dysfunction of the cells. The inventors have shown that inhibitors of fibril formation can be used to inhibit the formation of fibrils *in vitro*.

Summary of the invention

The inventors have now identified compounds that can be used to inhibit, reduce or disrupt amyloid deposits *in vivo*. In particular the compounds can be used against amyloid deposits of IAPP *in vivo*. Thus the invention provides methods and

compositions which are useful in the treatment of amyloidosis In particular, methods and compositions are disclosed for inhibiting, preventing and treating amyloid deposition, for example, in pancreatic islets wherein the amyloidotic deposits to be treated are, in an embodiment, islet amyloid polypeptide (IAPP)-associated amyloid deposits, e g , having at least some β-sheet structure The methods of the invention involve administering to a subject a therapeutic compound which inhibits, reduces or disrupts amyloid deposits, e.g , IAPP-associated amyloid deposits Accordingly, the compositions and methods of the invention are useful for inhibiting amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes

In one embodiment, a method for inhibiting amyloid deposition, particularly IAPP-associated amyloid deposition, in a subject is provided, wherein an effective amount of an IAPP fibril inhibiting compound, or a pharmaceutically acceptable salt thereof, is administered to the subject such that said IAPP-associated amyloid deposition is inhibited. Such compounds include those of the following general formula (a).



wherein k, m, t, p and q are independently 0 or 1; n is an integer from 0 to 3; C is a carbon; N is a nitrogen; W is hydrogen or an anionic group at physiological pH; Y is an anionic group at physiological pH; R^1 and R^2 are independently hydrogen, alkyl, an anionic group at physiological pH, or R^1 and R^2, taken together with the nitrogen to which they are attached, may form an unsubstituted or substituted heterocycle having from 3 to 7 atoms in the heterocyclic ring; R^3 is hydrogen, halogen, thiol or hydroxyl; R^4, R^5 and R^6 are independently hydrogen or halogen; and A is hydrogen or C_1 to C_6 alkyl; or a pharmaceutically acceptable ester, acid or salt thereof.

Preferred therapeutic compounds include 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid, DL-2-amino-5-phosphovaleric acid; 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine, cyclohexylsulfamic acid, *O*-phospho-*L*-serine, hexafluoroglutaric acid, 8-methoxyquinoline-5-sulfonic acid, 3-amino-2-hydroxy-1-propanesulfonic acid, and 3-dimethylamino-1-propanesulfonic acid, and pharmaceutically acceptable esters, acids or salts thereof

In another embodiment a method for inhibiting amyloid deposition, particularly IAPP-associated amyloid deposition, in a subject is provided, wherein an effective amount of an IAPP fibril inhibiting compound, or a pharmaceutically acceptable ester, acid or salt thereof, is administered to the subject such that said IAPP-associated amyloid deposition is inhibited Such compounds include those of the following general formula (b)



wherein C is a carbon; N is a nitrogen; H is a hydrogen; A^1, A^2, A^3, A^4, A^5 and A^6 are independently alkyl, O, S, or -NH; m and n (for each individual A group) are independently 0 or 1; p, q and l are independently 0, 1, or 2; R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, and each R^{14} are independently hydrogen, alkyl, alicyclyl, heterocycyl or aryl, each R^{13} is independently hydrogen, alkyl, alicyclyl, heterocycyl, aryl or an anionic group, and adjacent R groups (e.g., R^7 and R^8) may form an unsubstituted or substituted cyclic or heterocyclic ring.

Preferred therapeutic compounds include 1,2,3,4-tetrahydroisoquinoline.In

another embodiment the invention relates to a method for reducing IAPP-associated amyloid deposits in a subject having IAPP-associated amyloid deposits, the method comprising administering to a subject an effective amount of an IAPP fibril inhibiting compound, or a pharmaceutically acceptable salt thereof, such that IAPP-associated amyloid deposits are reduced

The therapeutic compounds of the invention are administered to a subject by a route which is effective for inhibiting IAPP-associated amyloid deposition Suitable routes of administration include oral, transdermal, subcutaneous, sublingual, buccal, intravenous and intraperitoneal injection The therapeutic compounds can be administered with a pharmaceutically acceptable vehicle.

The invention further provides pharmaceutical compositions for treating amyloidosis The pharmaceutical compositions include a therapeutic compound of the invention in an amount effective to inhibit IAPP-associated amyloid deposition, and a pharmaceutically acceptable vehicle.

The inventors have also found that the culturing of cells *in vitro* can lead to the formation of fibrils from endogenous proteins. Since the process is progressive, the fibrils are likely to continue to grow after the cells are transplanted and cause the death or dysfunction of the cells. This may occur even when the cells are from a healthy donor and when the patient receiving the transplant does not have a disease that is characterised by the presence of fibrils. The inventors have shown that the culturing of islet cells from a non-diabetic donor for the purpose of transplantation into a patient with type I diabetes leads to the formation of fibrils in cell clusters *in vitro*. They have also shown that inhibitors of fibril formation can be used to reduce the formation of fibrils *in vitro*.

Thus the invention also provides a process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming fibrils, said process comprising contacting the cells with an inhibitor of fibril formation. Any inhibitor of fibril formation may be used, including any such compounds mentioned herein.

The invention also provides a culture medium or culture medium pre-mix that comprises an inhibitor of the invention. The invention further provides *ex vivo* cells

made by the process of the invention The invention provides the *ex vivo* cells for use in a method of treatment of the human or animal body by therapy In particular the invention provides *ex vivo* cells of the invention which are islet cells for use in a method of treating diabetes

Brief description of the drawings

Figure 1 shows the effect of candidate substances on the proportion of non-fibrillar IAPP in a mixture of fibrils and non-fibrillar IAPP at time 0 and after incubation over a period of 24 h. The unshaded columns show results at time 0 and the shaded columns show results at time 24 h The vertical axis shows the proportion of non-fibrillar IAPP in the supernatent (as a percentage of control). Changes in the direction of the arrow represent a relative increase in non-fibrillar IAPP (decrease in fibrils)

Figure 2 shows the effect of polyvinylsulfonate (A) and compound vi (C), compared to IAPP alone (B), on formation of fibrils. The vertical axis shows fluorescence units. The horizontal axis shows time in hours.

Figure 3 shows the effects of compounds i, iii, x and iv on molecular conformation of the peptide as measured by circular dichroic spectroscopy at time 0 (left) and time 24 h (right). The horizontal axis shows the wave length.

Figures 4a and 4b show respectively isolated human and mouse islet cells which have been cultured for 6 days in glucose and RPM1. Amyloid fibrils can be seen between the cells (as shown by arrows). The dots show fibrils which have been immunogold labelled for IAPP.

Figure 5 shows the fibrils formed by IAPP alone or in the presence of candidate substances.

Figure 6 shows mean islet survival in the presence of the compounds. (A) represents guandinoethanosulfonic acid.

Detailed description of the invention

The present invention will be more fully illustrated by reference to the definitions set forth below

"Amyloid" includes IAPP-associated amyloid, including, but not limited to, β-sheet amyloid assembled substantially from IAPP subunits "Inhibition" of amyloid deposition includes preventing or stopping of IAPP-associated amyloid formation, inhibiting or slowing down of further IAPP-associated amyloid deposition in a subject with ongoing amyloidosis, e.g., already having amyloid deposits, and reducing or reversing IAPP-associated amyloid deposits in a subject with ongoing amyloidosis. Inhibition of amyloid deposition is determined relative to an untreated subject, or relative to the treated subject prior to treatment, or, e.g , determined by clinically measurable improvement in pancreatic function in a diabetic patient

Pharmaceutically acceptable salts of the therapeutic compound, where applicable, are within the scope of the invention, e.g., alkali metal, alkaline earth metal, higher valency cation (e.g., aluminum salt), polycationic counter ion or ammonium salts Where a compound is anionic, a preferred pharmaceutically acceptable salt is a sodium salt. Other salts are also contemplated, e.g., HCl, citric acid, tartaric acid salts, within their pharmaceutically acceptable ranges.

The therapeutic compound of the invention can be administered in a pharmaceutically acceptable vehicle. As used herein "pharmaceutically acceptable vehicle" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like which are compatible with the activity of the compound and are physiologically acceptable to the subject. An example of a pharmaceutically acceptable vehicle is buffered normal saline (0.15 molar NaCl). Except insofar as any conventional media or agent is incompatible with the therapeutic compound, use thereof in the compositions suitable for pharmaceutical administration is contemplated. Supplementary active compounds can also be incorporated into the compositions.

An "anionic group," as used herein, refers to a group that is negatively charged at physiological pH (for example at pH 6.6) or at a pH at which mammalian cells can be cultured (for example any such pH ranges mentioned herein). Preferred

anionic groups include carboxylate, sulfate, sulfonate, sulfinate, sulfamate, tetrazolyl, phosphate, phosphonate, phosphinate, and phosphorothioate or functional equivalents thereof "Functional equivalents" of anionic groups include bioisosteres, e g , bioisosteres of a carboxylate group Bioisosteres encompass both classical bioisosteric equivalents and non-classical bioisosteric equivalents Classical and non-classical bioisosteres are known in the art (see, e g , Silverman, R B *The Organic Chemistry of Drug Design and Drug Action*, Academic Press, Inc.: San Diego, CA, 1992, pp 19-23). A particularly preferred anionic group is a carboxylate

The term "alkyl" includes saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e g , C_1-C_{30} for straight chain, C_3-C_{30} for branched chain), and more preferably has 20 or fewer carbon atoms in the backbone. Likewise, cycloalkyls may have from 4-10 carbon atoms in their ring structure, more preferably have 5, 6 or 7 carbons in the ring structure.

Moreover, the term alkyl includes both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An "aralkyl" moiety is an alkyl substituted with an aryl (e.g.,

phenylmethyl (benzyl))

The term "aryl" herein includes 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like Aryl groups also include polycyclic fused aromatic groups such as naphthyl, quinolyl, indolyl, and the like Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles", "heteroaryls" or "heteroaromatics" The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin).

The terms "alkenyl" and "alkynyl" include unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

Unless the number of carbons is otherwise specified, "lower alkyl" means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. Likewise, "lower alkenyl" and "lower alkynyl" have similar chain lengths. Preferred alkyl groups are lower alkyls.

The terms "heterocyclyl" or "heterocyclic group" include 3- to 10- membered ring structures, more preferably 4- to 7- membered rings, which ring structures include one to four heteroatoms. Heterocyclyl groups include pyrrolidine, oxolane, thiolane, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones

and pyrrolidinones, sultams, sultones, and the like The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety

The terms "polycyclyl" or "polycyclic group" include two or more cyclic rings (e g , cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e g , the rings are "fused rings" Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety.

The term "heteroatom" includes an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.

The term "aryl aldehyde," as used herein, includes compounds represented by the formula Ar-C(O)H, in which Ar is an aryl moiety (as described above) and -C(O)H is a formyl or aldehydo group.

It will be noted that the structure of some of the compounds of this invention includes asymmetric carbon atoms. It is to be understood accordingly that the

isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis Furthermore, alkenes can include either the E- or Z- geometry, where appropriate

The present methods and compositions, in embodiments, inhibit, prevent and treat amyloid deposition in pancreatic islets wherein the amyloidotic deposits to be treated are islet amyloid polypeptide (IAPP)-associated amyloid deposits, e.g., having at least some β-sheet structure. The methods of the invention include administering to a subject a therapeutic compound which inhibits, reduces or disrupts IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes

In one embodiment, a method for inhibiting IAPP-associated amyloid deposition in a subject is provided, wherein an effective amount of an IAPP fibril inhibiting compound, or a pharmaceutically acceptable salt thereof, is administered to the subject such that said IAPP-associated amyloid deposition is inhibited. Such compounds include those of the following general formula (a)



wherein k, m, t, p and q are independently 0 or 1; n is an integer from 0 to 3; C is a carbon, N is a nitrogen; W is hydrogen or an anionic group at physiological pH; Y is an anionic group at physiological pH; R^1 and R^2 are independently hydrogen, alkyl, an anionic group at physiological pH, or R^1 and R^2, taken together with the nitrogen to which they are attached, may form an unsubstituted or substituted heterocycle having from 3 to 7 atoms in the heterocyclic ring; R^3 is hydrogen, halogen, thiol or

hydroxyl, R^4, R^5, and R^6 are independently hydrogen or halogen; and A is hydrogen or C_1 to C_6 alkyl, or a pharmaceutically acceptable salt thereof.

In an embodiment, W is preferably -COOH. Y is preferably -COOH, $-SO_3H$, $-PO_3H_2$ or $-OP(O)(OH)_2$, R^1 is preferably H, Me or hydroxypropyl, R^2 is preferably H, Me or $-SO_3H$. R^3 is preferably H, F, or OH, when R^1 and R^2, taken together with the nitrogen to which they are attached, form an unsubstituted or substituted heterocycle, preferred groups include







R^4, R^5 and R^6 are preferably H or F, A is preferably H, CH, CF_2 or alkyl which may be substituted or unsubstituted, straight, branched or cyclic, e.g., cyclohexyl.

Preferred therapeutic compounds include 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid; DL-2-amino-5-phosphovaleric acid; 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine; cyclohexylsulfamic acid; *O*-phospho-*L*-serine; hexafluoroglutaric acid; 8-methoxyquinoline-5-sulfonic acid; 3-amino-2-hydroxy-1-propanesulfonic acid; and 3-dimethylamino-1-propanesulfonic acid, and pharmaceutically acceptable salts thereof.

In another embodiment a method for inhibiting IAPP-associated amyloid deposition in a subject is provided, wherein an effective amount of an IAPP fibril inhibiting compound, or a pharmaceutically acceptable salt thereof, is administered to the subject such that said IAPP-associated amyloid deposition is inhibited. Such compounds include those of the following general formula (b)



wherein C is a carbon, N is a nitrogen, H is a hydrogen; A^1, A^2, A^3, A^4, A^5 and A^6 are independently alkyl, O, S, or -NH, m and n (for each individual A group) are independently 0 or 1; p, q and l are independently 0, 1, or 2, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, and each R^{14} are independently hydrogen, alkyl, alicyclyl, heterocycyl or aryl, each R^{13} is independently hydrogen, alkyl, alicyclyl, heterocycyl, aryl or an anionic group, and adjacent R groups (e.g., R^7 and R^8) may form an unsubstituted or substituted cyclic or heterocyclic ring.

Preferred therapeutic compounds include 1,2,3,4-tetrahydroisoquinoline.

A further aspect of the invention includes pharmaceutical compositions for treating amyloidosis. The therapeutic compounds in the methods of the invention, as described hereinbefore, can be incorporated into a pharmaceutical composition in an amount effective to inhibit amyloidosis or reduce amyloid deposits, in a pharmaceutically acceptable vehicle.

In the methods of the invention, amyloid deposition in a subject is inhibited by administering a therapeutic compound of the invention to the subject. The term subject includes living organisms in which amyloidosis can occur. Examples of subjects include humans, apes, monkeys, cows, sheep, goats, dogs, cats, mice, rats, and transgenic species thereof, as well as cells therefrom, e.g., islet cells, in culture. Administration of the compositions of the present invention to a subject to be treated can be carried out using known procedures, at dosages and for periods of time

effective to inhibit amyloid deposition or reduce amyloid deposits in the subject An effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the amount of amyloid already deposited at the clinical site in the subject, the age, sex, and weight of the subject, and the ability of the therapeutic compound to inhibit amyloid deposition or reduce amyloid deposits in the subject Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The active compound may be administered by routes such as oral, sublingual, buccal, transdermal, subcutaneous, intravenous, and intraperitoneal administration. Depending on the route of administration, the active compound may be coated in a material to protect the compound from the action of acids, enzymes and other natural conditions which may inactivate the compound

The compounds of the invention can be formulated to ensure proper distribution *in vivo*. For example, the therapeutic compounds of the invention can be formulated, for example, in liposomes. For methods of manufacturing liposomes, see, e.g., U.S. Patents 4,522,811; 5,374,548; and 5,399,331. The liposomes may comprise one or more moieties which are selectively transported into specific cells or organs ("targeting moieties"), thus providing targeted drug delivery (see, e.g., V.V. Ranade (1989) *J. Clin. Pharmacol.* 29:685). Exemplary targeting moieties include folate or biotin (see, e.g., U.S. Patent 5,416,016 to Low *et al.*); mannosides (Umezawa *et al.*, (1988) *Biochem. Biophys. Res. Commun.* 153:1038); antibodies (P.G. Bloeman *et al.* (1995) *FEBS Lett.* 357:140; M. Owais *et al.* (1995) *Antimicrob. Agents Chemother.* 39:180); surfactant protein A receptor (Briscoe *et al.* (1995) *Am. J. Physiol.* 1233:134); gp120 (Schreier *et al.* (1994) *J. Biol. Chem.* 269:9090); see also K. Keinanen; M.L. Laukkanen (1994) *FEBS Lett.* 346:123; J.J. Killion; I.J. Fidler (1994) *Immunomethods* 4:273. In a preferred embodiment, the therapeutic compounds of the invention are formulated in liposomes; in a more preferred embodiment, the liposomes include a targeting moiety.

To administer the therapeutic compound by other than parenteral

administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. For example, the therapeutic compound may be administered to a subject in an appropriate carrier, for example, liposomes, or a diluent. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan *et al.*, (1984) *J. Neuroimmunol* 7:27).

The therapeutic compound may also be administered parenterally, sublingually, buccally, intraperitoneally, intraspinally, or intracerebrally. Dispersions can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The vehicle can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.

Sterile injectable solutions can be prepared by incorporating the therapeutic

compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization Generally, dispersions are prepared by incorporating the therapeutic compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yield a powder of the active ingredient (i.e., the therapeutic compound) plus any additional desired ingredient from a previously sterile-filtered solution thereof

The therapeutic compound can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The therapeutic compound and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet For oral therapeutic administration, the therapeutic compound may be incorporated with excipients and used in the form of ingestible tablets, sublingual/buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. The percentage of the therapeutic compound in the compositions and preparations may, of course, be varied. The amount of the therapeutic compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such a therapeutic compound for the treatment of amyloid deposition in subjects.

Active compounds are administered at a therapeutically effective dosage sufficient to inhibit amyloid deposition in a subject. A "therapeutically effective

dosage" preferably inhibits amyloid deposition and/or reduces amyloid deposits by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects or to the same subject prior to treatment

The ability of a compound to inhibit amyloid deposition or reduce amyloid deposits can be evaluated in an animal model system that may be predictive of efficacy in inhibiting amyloid deposition or reducing amyloid deposits in human diseases The ability of a compound to inhibit amyloid deposition can also be evaluated by examining the ability of the compound to inhibit amyloid deposition *in vitro* or *ex vivo*, e g , using an ELISA assay The effect of a compound on the secondary structure of the amyloid can be further be determined by circular dichroism (CD) or infrared (IR) spectroscopy

CD and IR spectroscopy are particularly useful techniques because the information obtained is a direct measure of the ability of a test compound to prevent or reverse amyloidosis, by determining the structural effect of a compound on amyloid protein folding and/or fibril formation This contrasts with previously known methods which measure cellular trafficking of amyloid protein precursors or interactions between amyloid and extracellular matrix proteins, providing only indirect evidence of potential amyloid-inhibiting activity. It should further be noted that CD and IR spectroscopy can also detect compounds which cause an increase in, e.g., β-sheet folding of amyloid protein, and thereby stabilize the formation of amyloid fibrils.

The deposition of amyloid is a multi-stage process. Accordingly, an agent useful for treating amyloidosis has many potential modes of action. An agent which inhibits amyloid deposition could act in one or more of the following ways, which are shown by way of illustration and not limitation:

1. Inhibition or delay of protein folding in solution
2. Inhibition or delay of aggregation of amyloid peptides into fibrils and/or deposits
3. Disruption/dissolution/modification of amyloid fibrils and/or deposits

Categories 1 and 2 correspond to prevention of the formation of amyloid

deposits (slowing down or halting amyloid deposition), and category 3 corresponds to removal or modification of deposits already formed (removal or reduction of existing amyloid deposits)

In another aspect the process of the invention aims to reduce the amount of amyloid deposits that are present in a cell preparation before transplantation As mentioned amyloid deposits will comprise at least some protein present in the form of fibrils

Such fibrils typically have an ordered and repeating structure created by the regular assembly of the protein components Typically a fibril is straight and unbranched. It is generally insoluble in the cytoplasm or in extracellular compartments The fibril may or may not be insoluble in distilled water, or organic solvents, such as hexafluoroisopropanol or trifluoroethanol. It typically has a diameter of 5 to 20 nm, for example 7 to 15 or 10 to 12 nm. The protein in the fibril generally forms one, two or more β-strands which are typically oriented substantially perpendicular to the long axis of the fibril and may form β-sheets that propagate substantially in the direction of the fibril twisting around each other. Fibrils are generally in the form of small linear aggregates of molecules in β-sheet construction or of filamentous structure of varying extended lengths.

Typically the protein that forms the fibril has at least 30%, such as at least 50 or 70% of its native structure as β-sheet. In the case of certain fibrils the native form of the protein (i.e. the soluble non-fibril form) has an α-helical region, which may in all or part be converted to a β-sheet structure in the fibril. The protein is typically a secreted extracellular protein, but may be an intracellular protein. The protein may be the wild-type or an alternative form, such as a mutated form. The alternative form can be a truncated form of the wild-type protein.

The protein is typically IAPP, Aβ peptide (involved in Alzheimer's disease), prion protein, immunoglobulin light chain, amyloid A protein, transthyretin, cystatin, β2-microglobulin, apolipoprotein A-1, gelsolin, calcitonin, atrial natriuretic factor, lysozyme variants, insulin, or fibrinogen.

The protein may be one which has sequence or structural homology with any of these particular proteins. Preferably the protein has sequence or structural

homology with IAPP The protein may be one which does not contain any tryptophan residues in its sequence

The inhibitor of fibril formation is able to reduce the amount of fibril formation that occurs in conditions in which fibril formation would occur Thus an inhibitor can be identified in an assay by contacting a candidate substance with a protein that forms fibrils under conditions in which fibril formation would occur and determining whether fibril formation is inhibited by the substance In one embodiment the inhibitor may interact with preformed fibrils to modulate their architecture resulting in the breaking of the fibrils into monomeric or small oligomeric peptide components The protein may be any of the proteins mentioned herein.

In the *in vitro* assay, changes in the proportion of monomeric/small oligomeric protein components in a mixture of protein and fibrils can be measured by assaying the non-fibrillar components The effects of candidate substances on fibril formation can also be measured using thioflavine T spectroscopy or circular dichroic spectroscopy Circular dichroic spectroscopy indicates the effect of the candidate substances on the molecular conformation of the soluble or other forms of non-fibrillar peptide. In particular, conversion of the molecule to β-conformation which indicates β-sheet formation.

In the assay the inhibitor typically inhibits fibril formation by at least 10%, at least 20%, at least 30%, at least 40% at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or at least 99.9% at a concentration of the inhibitor of 10ng ml^{-1}, 100ng ml^{-1}, 1μg ml^{-1}, 10μg ml^{-1}, 100μg ml^{-1}, 500μg ml^{-1}, 1mg ml^{-1}, 10mg ml^{-1} or 100mg ml^{-1}, or a molarity of inhibitor of 100nM, 1μM, 10μM, 100μM, 1mM, 10mM or 100mM. In one embodiment such effects are measured over 24 hours in an assay in which the concentration of the monomeric protein is 20μM. The percentage inhibition represents the percentage decrease in amount of fibril formation in a comparison of assays in the presence and absence of the test substance. Any combination of the above mentioned degrees of percentage inhibition and concentration of inhibitor may be used to define an inhibitor of the invention, with greater inhibition at lower concentrations being preferred.

An inhibitor of IAPP fibril formation typically causes any of the above percentage inhibition at any of the above concentrations or molarities when contacted with an 80 μg/ml solution of human IAPP in distilled water, at 25°C, over 24 hours

The inhibitor is typically non-toxic towards the cells (e g in culture), for example at any of the concentrations mentioned above The inhibitor may be non-toxic towards any of the mammals mentioned herein, and thus maybe pharmaceutically acceptable The inhibitor may or may not be able to enter the cells, typically by diffusing across the cell membrane

The inhibitor may prevent the neoformation and/or growth of fibrils and/or may breakdown any preformed fibrils which are present The inhibitor typically binds to the monomeric form of the protein and prevents it oligomerising to form the fibril The inhibitor may bind to the multimeric form to prevent further protein binding and/or modulate the structure of the multimeric form to cause breakdown of the multimeric form into its component peptide fragments Such a binding may be reversible or non-reversible. The binding may cause a change in the structure of the monomeric or multimeric form of the protein and/or a change in the structure of the inhibitor. In one embodiment the surface of the inhibitor mimics the part of the surface of the monomeric form which will bind the multimeric form.

The inhibitor may be congo red (e.g as described in WO 94/01116), an acridinone or related molecule (e.g. as described in WO 97/16191), a naphthylazo compound (e.g. as described in WO 97/16194), hexadecyl-N-methylpiperidinium bromide (*J. Biol. Chem.* (1986) **271** (8), 4086-4092), or a saccharide or saccharide composition (e.g. as described in WO 99/0999). The inhibitor may be a peptide or a substituted peptide as described in *J. Am. Chem. Soc.* (1998) **120**, 7655-7656. The inhibitor may be an organic solvent (e.g. dimethylsulphoxide or polyethyleneglycol).

The inhibitor may be of the formula (a) or (b), including any of the specific embodiments or specific compounds covered by (a) or (b) which are discussed above.

Preferably the inhibitor is any one of compounds (i) to (x) below or a pharmaceutically acceptable salt thereof:

(i) 3-(3-hydroxy-1-propyl) amino-1- propanesulfonic acid

$HOCH_2CH_2CH_2NHCH_2CH_2CH_2SO_3H$,

(ii) DL-2-amino-5-phosphovaleric acid



(iii) 1, 2, 3, 4 - tetrahydroisoquinoline



(iv) Cyclohexylsulfamic acid



(v) O-Phospho-L-serine



(vi) Hexafluoroglutaric acid



(vii) 8-methoxyquinoline-5-sulfonic acid



(viii) 4-phenyl-1- (3' sulfopropyl)- 1, 2, 3, 6 - tetrahydropyridine



(ix) - 3-amino-2-hydroxy-1- propanesulfonic acid



(x) 3-dimethylamino-1-propanesulfonic acid

$Me_2NCH_2CH_2CH_2SO_3H$

Compound No	Form of Compound	CAS Number	Supplier
i		58431-88-2	Neurochem Inc.
ii		76326-31-3	Sigma-Aldrich
iii	Hydrochloride	14099-81-1	Sigma-Aldrich
iv	Sodium salt	139-05-9	Sigma-Aldrich
v		407-41-0	Sigma-Aldrich
vi		376-73-8	Sigma-Aldrich
vii		40712-20-7	Sodium salt available from Neurochem Inc.
viii	Sodium salt		Neurochem Inc.
ix		7013-33-4	Neurochem Inc.
x		29777-99-9	Neurochem Inc.

In the discussion below the term 'specific inhibitor' includes any of the compounds discussed herein, such as those described by either of the general formulae (a) or (b) or their salts (including (i) to (x) above as well as their salts discussed above) The inhibitor of the invention may be structurally and/or functionally equivalent to any of the specific inhibitors Thus the inhibitor of the invention may be capable of competing with any of the specific inhibitors to bind the monomeric or multimeric form of the protein Thus the inhibitor may bind the monomeric or multimeric form at the same place as any of the specific inhibitors. The inhibitor may mimic the surface of any of the specific inhibitors Thus the inhibitor of the invention may bind to an antibody that binds to the specific inhibitors, and thus may be capable of inhibiting the binding of the antibody to the specific inhibitor Such an antibody can be made by known methods, including administering the specific inhibitor to an animal in association with a carrier to make it more immunogenic. The inhibitor may mimic the shape, size, flexibility or electronic configuration of any of the specific inhibitors. It is typically a derivative of any of the specific inhibitors.

The antibody may be used to identify inhibitors from libraries of compounds, such as combinatorial libraries. Alternatively inhibitors which mimic the specific inhibitors may be designed computationally and made by synthetic chemistry techniques.

The cells of the invention are generally going to be transplanted into a patient suffering from a disease. The disease may or may not be a disease in which fibrils are present in the patient. In the case of diseases in which fibrils are present in the patient the fibrils may cause the disease, or at least some of the symptoms of the disease. The fibrils may be formed because of the disease, and may exacerbate the symptoms of the disease. The disease may be type I or type II diabetes, Alzheimer's disease, a spongiform encephalopathy, primary or secondary systemic amyloidosis, familial amyloidotic polyneuropathy, senile systemic amyloidosis, hereditary cerebral amyloid angiopathy, haemodialysis-related amyloidosis, Finnish hereditary amyloidosis, medullary carcinoma of the thyroid, atrial amyloidosis, lysozyme amyloidosis, or fibrinogen α-chain amyloidosis.

In the disease fibrils may form in a particular tissue, and thus may affect a particular type or types of cells The fibrils may be made of a protein produced by such cells Alternatively the fibrils may be made of a protein which is produced in a different type of cell or tissue The fibrils may be located in an intracellular compartment of the cells, such as in the cytoplasm or cytoplasmic organelles Alternatively the fibrils are located in the extracellular compartment, for example in the proximity of or contacting the cells, which have produced the protein from which the fibrils are made

Alternatively in the disease the cells may be affected by other factors which are not connected with fibrils, for example by an autoimmune attack or pathogenic infection, such as a bacterial or viral infection The disease may be type I diabetes Such cells being affected in the disease may be the same as or different from the cells discussed herein The cells of the invention are capable of forming fibrils or susceptible to the deleterious effect of fibrils

Typically fibrils damage cells by causing a decrease in the amount of substances produced (or secreted) by the cells, or kill the cells or induce apoptosis and cell death.

Thus the *ex vivo* cells of the invention are typically of the same or similar type as the cells which have been affected by the disease. The process of the invention is applicable to cells that can form fibrils after transplantation, which as discussed above typically also form fibrils when in culture. In one embodiment the *ex vivo* cells are in a preparation that comprises the inhibitor.

The cells are mammalian cells, such as human, primate, rodent, rabbit, ovine, porcine, bovine, feline or canine cells. The cells are typically cells that naturally express a protein that is capable of forming a fibril. In one embodiment the cells are endocrine cells. The cells may be islet, liver, muscle, kidney or neuronal cells. In one embodiment the cells are genetically modified, and are, for example, capable of expressing genes not naturally expressed by the cell. In one embodiment the cells are islet cells and the fibrils comprise human islet amyloid polypeptide.

The cells of the invention are typically from a donor who generally does not have the relevant disease. In one embodiment the cells are from the patient. The

cells may be take from the patient to increase their numbers in vitro and/or the cells may be treated therapeutically in some manner before administering them back to the patient For example the cells may be treated with agents, which act against (e g kill) pathogens

The cells can be obtained from the donor or patient by standard techniques Before being cultured the cells are generally further purified, for example using collagenase dissociation and/or density gradient centrifugation techniques or cell sorting techniques

The cells are contacted with the inhibitor before transplantation Generally the cells are contacted with the inhibitor when being cultured Thus in the process the cells are cultured in the presence of the inhibitor However, in one embodiment the cells are contacted with inhibitor after culturing, but before transplantation, for example in the case of inhibitors which cause breakdown of pre-existing fibrils In one embodiment of the process the fibrils are initially present in the said cells prior to contacting with said inhibitor and said inhibitor causes breakdown of said fibrils. The inhibitor may cause breakdown of some or of all the fibrils present.

The cells are typically cultured in order allow them to recover after the isolation procedure, to increase their numbers before transplantation, to treat them therapeutically in some manner or to change the proportion of the different types of cells present in the culture. In order to achieve this last aim the cells may be cultured in conditions which allow the survival of certain types of cells over other types of cells. In one embodiment the cells are cultured in conditions which reduce the numbers of 'passenger' leukocytes in order to reduce the immunogenicity of the cells.

Typically cells are cultured for from 12 to 150 hours, for example from 24 to 100 hours, before transplantation. Generally the cells are cultured at from 20°C to 45°, for example 30°C to 40°C, preferably 35°C to 37°C. Generally the pH of the culture is from 6.6 to 8.0, preferably 7 to 7.6 or 7.2 to 7.4. Thus the cells of the invention may be cells which have been cultured under such conditions and/or in the culture medium discussed below.

Generally the cells are cultured in the culture medium of the invention which

comprises an inhibitor of the invention Such a medium is capable of providing support for any of the cells of the invention Thus the medium will provide substances to keep the cells alive, and may also allow growth and replication of the cells The medium thus comprises nutrition for the cells The nutrition will be in the form of an assimible carbon source, such as a carbohydrate source or amino acids. Thus the medium may comprise sugars, such as glucose, fructose, mannose or galactose or non-sugar carbohydrates, such as lactate or pyruvate These may be present at from 1 to 40 mM, such as 10 to 30 mM The medium may comprise an amino acid, such as arginine, cysteine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, tyrosine or valine.

The medium comprises water. The medium may comprise ions from inorganic salts, such as sodium, potassium, calcium, magnesium, iron, selenium, carbonate, phosphate or sulphate ions The medium may comprise vitamins, such as nicotinamide. The medium may comprise xanthine

The medium may comprise growth factors or hormones. The medium may comprise proteins, such as binding and transport proteins, for example transferrin or albumin The medium may comprise lipids, insulin or ethanolamine.

Some of the above components may be provided in the medium by an extract from an animal or equivalent supplements. Thus the medium may comprise such an extract. The extract may be partially purified. The extract may be serum, such as foetal calf serum.

The medium may comprise antibiotics, such as penicillin.

The medium may comprise the constituents of the commercially available mediums which can be obtained from NBL™ or Gibco™, such as RPMI 1640™, Dulbecco's modified Eagle's medium™, Medium 199™, CMRL 1066™.

In the medium the inhibitor is typically present at a concentration of 1 to 10,000 μM, for example 10 to 1000 μM or 100 to 500 μM.

The culture medium pre-mix typically has the same constituents as the culture medium but contains less water, such as less than from 50%, 10%, 1% or 0.1% of the water present in the culture medium. The pre-mix may be in the form of a liquid, gel or powder. Typically the pre-mix can be converted to a culture medium by adding

water

The culture medium may comprise a precursor of the inhibitor which provides the inhibitor when contacted with any of the cells discussed above. The pre-mix may comprise a precursor which provides the inhibitor when contacted with water or with the cells. The term 'inhibitor' includes such precursors

The culture of the invention comprises the cells of the invention and culture medium of the invention. The culture comprises at least 100 cells, such as at least 10^3, 10^5, 10^7 or 10^9 cells

The inhibitor may also be administered to a patient who has received a transplant of the cells of the invention. The inhibitor is administered to prevent damage *in vivo* to the transplanted cells by fibrils. Thus the invention provides an inhibitor for use in inhibiting fibril formation by, or breaking fibrils down in, a transplanted cell preparation

The invention also provides a vessel for containing a culture of cells, which vessel is coated with the inhibitor. The vessel may be a Petri dish or a flask. The vessel may comprise glass or plastic. The inhibitor is generally present on the surface which will be in contact with the culture. The inhibitor is present in a form in which it is capable of being released into the culture when the culture comes into contact with it.

The invention also provides a kit for culturing cells comprising the culture medium or pre-mix of the invention or a vessel of the invention.

Antibodies that bind to the inhibitors of the invention may be used to screen for inhibitors based on their ability to bind the antibody. Typically such a screening is carried out on a library of candidate compounds. Thus the invention provides use of an antibody that binds an inhibitor of the invention, or of a fragment that retains the ability of said antibody to bind said inhibitor, to identify a compound that can be used to prepare cells for transplantation in the process of the invention.

Inhibitors can also be identified based on their ability to inhibit the formation of fibrils or breakdown fibrils in a cell preparation that comprises any of the types of cells mentioned herein which can be treated in the process of the invention. Thus the invention provides a method of identifying an inhibitor that can be used to prepare

cells for transplantation in a process of the invention, comprising contacting a candidate substance with a mammalian cell and determining whether the candidate substance inhibits the formation of fibrils or causes the breakdown of fibrils, (i) the inhibition of formation of fibrils or (ii) the breakdown of fibrils, indicating that the substance is an inhibitor that can be used in said process The cell is typically a human islet cell

The inhibitor may also identified based on its ability to breakdown fibrils or to inhibit the formation of fibrils Thus the invention provides a method of identifying an inhibitor that can be used to prepare cells for transplantation in a process of the invention, comprising contacting a candidate substance with a protein capable of forming fibrils, or with a fibril, and determining whether the substance inhibits the formation of the protein into a fibril, or whether the substance causes the breakdown of the fibril, (i) inhibition of fibril formation or, (ii) the breakdown of fibrils, indicating that the substance can be used in said process The protein is typically human islet amyloid peptide or the fibrils are typically made of human islet amyloid peptide.

The invention also provides an inhibitor identified in the use and method of the invention Such an inhibitor may be used in any of the aspects of the invention discussed herein, or may be used in a method of treatment of the human or animal body by therapy Thus the invention also provides a process, culture medium pre-mix, *ex vivo* cell, pharmaceutical composition vessel or kit of the invention wherein the inhibitor is an inhibitor that has been identified in the use or method of the invention.

A therapeutically effective number of cells of the invention may be administered to a human or animal in need of treatment. Diseases which may be treated using the cells of the invention are those in which a particular cell type is malfunctioning or has died. The condition of a patient suffering from such a disease can thus be improved.

Thus the invention provides cells of the invention for use in a method of treatment of the human or animal body by therapy, in particular for use in a method of treating diabetes. The invention also provides use of any of the cells of the

invention in the manufacture of a medicament for the treatment of a disease in which a particular cell type is malfunctioning or has died, in particular for the treatment of diabetes Thus the invention provides a method of treating a disease in which a particular cell type is malfunctioning or has died comprising administering a cell of the invention to an individual with the disease

The term "transplantation" refers to any method of administering cells Thus in one embodiment a surgical procedure the cells are placed in the relevant part of the body The cells may be administered by direct injection into the relevant site Preferably the cells are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline The composition is typically formulated for intravenous or subcutaneous administration, or for administration by transplantation

In one embodiment the cells are encapsulated. Generally the encapsulating material is permeable to nutrients (such as sugars or amino acids), but impermeable to immune mediators (such as antibodies or complement components) or cells

Typically the material comprises alginate (alternating blocks of mannuronic and guluronic acid) such as in the form of barium and/or poly-L-lysine alginate. The material may comprise hollow fibres (such as acrylic, polyacrylonitrile vinyl chloride or polyethersulfone). The material may comprise hydroxyethyl-methacrylate-methyl-methacrylate, polyphosphazene or agarose.

The dose of cells which are administered to a patient will depend upon a variety of factors such as the age, weight and general condition of the patient, the disease that is being treated and the particular cells that are being administered. A suitable dose may however be from 0.1 to 100 mg/kg body weight such as 1 to 40 mg/kg body weight, or 10^3 to 10^7 cells. The routes of administration and dosages described above are intended only as a guide since a skilled physician will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

The inhibitor is administered to a patient by a route which is effective for preventing damage to transplanted cells by fibrils. Suitable routes of administration

and dosages have been discussed above Generally an effective non-toxic amount of the inhibitor is administered The inhibitor is typically administered in the form of a pharmaceutical composition comprising the inhibitor in association with a pharmaceutically acceptable carrier or diluent The inhibitor may be administered in any of the forms discussed above, for example with any of the pharmaceutically acceptable vehicles mentioned above The inhibitor may be present in any of these forms when it is used in the *in vitro* process of the invention

The invention is further illustrated by the following examples which should not be construed as further limiting the subject invention The contents of all references, issued patents, and published patent applications cited throughout this application are hereby incorporated by reference

Example 1

Determination of the rate of amyloid fibril formation by Thioflavine T spectroscopy

Thioflavine T (ThT) binds to amyloid proteins in β-sheet formation, exhibiting a yellow fluorescence from tissue sections and fibrils *in vitro* Detection of ThT fluorescence can be used as a sensitive assay for amyloid fibril formation under different conditions. This assay has been used in experiments to determine the effects of compounds of the invention on amyloid fibril formation.

Method

Human IAPP was dissolved in 40% trifluoroethanol and freeze-dried into conveniently-sized aliquots. IAPP was prepared immediately before the measurements by dissolving in 40% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) in water to maintain the peptide in alpha helical conformation and soluble. A stock solution of ThT (2.5mM) was prepared, 7.9mg in 10mL Tris-HCl pH 7.0 and filtered (0.22 μm). Solutions were kept in the dark until use. Fluorescence was examined at 440nm excitation (slit 5nm), and emission at 482nm (slit 10nm) with stirring. 25ml of ThT stock (final concentration 62.5 μM) was added to peptide sample and made up to 1mL in the cuvette. The sample was stirred for 5 min. before taking a reading. Measurements were made at an initial time point (5 min. from sample preparation), at intervals over the next 4-6h and after overnight incubation at room temperature.

Certain compounds as disclosed herein, i e , 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid, DL-2-amino-5-phosphovaleric acid, 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine, cyclohexylsulfamic acid, *O*-phospho-*L*-serine, hexafluoroglutaric acid, 8-methoxyquinoline-5-sulfonic acid, 3-amino-2-hydroxy-1-propanesulfonic acid, and 3-dimethylamino-1-propanesulfonic acid, and 1,2,3,4-tetrahydroisoquinoline, were found to inhibit or prevent IAPP-associated fibril assembly

Example 2

Circular dichroism analysis was conducted to confirm the activity of certain therapeutic compounds in preventing or inhibiting IAPP-associated fibril formation in accordance with the present disclosure by determining the presence or absence of ß-sheet conformation

The assay is conducted as follows:

INSTRUMENT AND PARAMETERS

Instrument: JASCO J-715 Spectropolarimeter

Cell/cuvette: Hellma quartz (QS) with 1 0 mm pathlength

Room temperature

Wavelength interval: 250 nm-190 nm

Resolution: 0.1 nm

Band width: 1.0 nm

Response time: 1 sec

Scanning speed: 20 nm/min

Number of spectra run: 5

The assay, a co-incubation procedure, examines the ability of a compound or substance to inhibit the assembly of amyloid fibrils, e.g., to test for the presence of the amyloidotic b-sheet conformation in the presence of soluble IAPP. Samples are run in the presence and absence (i.e., water alone) of buffering agent, which is done to determine if competitive effects are seen with the ionic buffer (usually phosphate).

A. Assay in Water Only

Add components used at a molar ratio of 1 10 [peptide compound]; add 10 µL of 10 mg/mL IAPP stock solution (final 100 µg peptide) to the aqueous solution containing compound to a final volume of 400 µl The pH of the final assay solution is measured to ensure there is no fluctuation and the spectrum is accumulated using the parameters as shown above

B. Assay in Phosphate Buffer

Add desired amount of compound to achieve a 1:10 molar ratio in 10 mM phosphate buffer, pH 7 Add 10 µL of 10 mg/mL IAPP stock solution (final peptide 100 µg) to the phosphate buffered solution containing the compound and bring to a final volume of 400 µL. The pH of the final assay solution is measured to ensure there is no fluctuation and the spectrum is accumulated using the parameters as shown above.

In both assays, a control sample is run with each test group This control contains peptide only in water or buffer at a similar final volume of 400 µl. Spectra for the control are collected initially (first run) and at the end of the test (final run) to ensure that the peptide has not undergone extensive aggregation during the course of the assay Spectra for the controls are used to compare with the measurements obtained with the treated samples.

CO-INCUBATION:

Make fresh 1 mg/mL stock solution of IAPP in 10 mM phosphate buffer, pH 7. Add desired amount of compound to achieve a 1:10 molar ratio in 10 mM phosphate buffer, pH 7. Incubate for 3 days at room temperature. Make up to final volume of 400 µL with 10 mM phosphate buffer, pH 7. The pH of the final assay solution is measured to ensure there is no fluctuation and the spectrum is accumulated using the parameters as shown above. A similar control is run for comparative purposes.

DATA ANALYSIS

Plots of the spectra (control and treated) are individually assembled and the changes in ellipticity at 218 nm are examined This minimum is directly correlated with the amount of peptide in β-sheet conformation present in the sample Changes in either a positive or negative direction are noted and a relative value ("active" or "not active") assigned to the compound as a measure of activity

Compound	Activity
3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid	Active
DL-2-amino-5-phosphovaleric acid	Active
1,2,3,4-tetrahydroisoquinoline, hydrochloride	Active
cyclohexylsulfamic acid, sodium salt	Active
O-phospho-L-serine	Active
hexafluoroglutaric acid	Active
8-methoxy-5-quinolinesulfonic acid, sodium salt	Active
4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine, sodium salt	Active
3-amino-2-hydroxy-1-propanesulfonic acid	Active
3-dimethylamino-1-propanesulfonic acid	Active

Example 3

The synthesis of a compound of the invention, 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine, sodium salt.

To a solution of 4-phenylpyridine (15.5 g, 0.1 mol) in acetone (100 mL) was added 1,3-propane sultone (12.2 g, 0.1 mol) at room temperature. The mixture was then heated at reflux temperature overnight. The resultant suspension was cooled to room temperature. The solid was collected by filtration and washed with acetone. To a solution of the solid (31 g) in methanol (500 mL) was added sodium borohydride (10 g, 260 mmol) portionwise, and the mixture was stirred at room temperature for 2 h. Distilled water (50 mL) was added to destroy the excess of sodium borohydride. The mixture was diluted with methanol (200 mL), and neutralized with Amberlite IR-120 ion-exchange resin (H^+ form, 300 g). A white precipitate was formed. The precipitate and the resin were removed by filtration and treated with distilled water (400 mL) at ~100 °C. The mixture was filtered and the

residual resin was washed with hot distilled water (2 x 200 mL). The filtrates and washings were combined and concentrated to dryness The residue was co-evaporated with methanol (3 x 200 mL), and then recrystallized from ethanol-water {8 2 (v/v)} to afford 4-phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine as white crystals (26 g, 93%) The ^1H and ^{13}C NMR spectra were in agreement with the structure

To a solution of 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine (5.6 g, 20 mmol) obtained above in ethanol (180 mL) was added sodium hydroxide (1.2 g, 30 mmol) The suspension was heated at reflux temperature for 30 min. The reaction mixture was then cooled to room temperature The first crop of product (3 9 g, 64% yield) was collected by filtration The filtrate was concentrated to dryness, and the residue was recrystallized from ethanol to afford a second crop of product (2 g, 32% yield)

^1H NMR (400 MHz, D_2O) δ 1.85 (quintet, 2 H, J 8.7, 7.7 Hz, 2 H-2'), 2.39-2.45 (m, 4H, 2 H-3' and 2 H-3), 2.59 (t, 2 H, J 5.6 Hz, 2 H-2), 2.80 (t, 2 H, J 7 7 Hz, 2 H-1'), 3.00 (br s, 2 H, 2 H-6), 6.00 (br s, 1H H-5), 7.18-7 36 (m, 5 H, Ar).

^{13}C NMR (100.6 MHz D_2O): δ 23.90 (C-2'), 29.01 (C-3), 51.69, 51.76 (C-2, C-3'). 54.45 (C-6), 58.12 (C-1'), 123.75 (C-5), 127.31, 130.01, 131.24 (Ar), 136.89 (C-4), 142.47 (Ar).

Example 4

ELISA assay for quantitative determination of fibril formation

Human IAPP (hIAPP) was synthesised by solid state synthesis (Advanced Biotechnologies, UK). Human IAPP forms fibrils immediately in aqueous media. Aliquots of IAPP in water (800µg/ml) were stored frozen at -20°C until use. These samples contain small numbers of fibrils visible with electron microscopy (em).

Two sets of samples containing IAPP (20µM) with or without inhibitors (at a molar ratio of 10:1 with IAPP, (20µM)) were prepared on day 1 in Tris buffer. One set was centrifuged, the supernatant removed and frozen immediately at -20°C (Time zero time point). The other set was incubated overnight at room temp with shaking (time 24h time point). On day 2 these samples were spun and supernatant removed

to determine the proportion of non-fibrillar IAPP.

To assay IAPP in the supernatant both sets of samples were serially diluted in bicarbonate coating buffer, added to ELISA wells and incubated overnight. Plates were washed in phosphate buffer containing Tween (PBS/Tw) x3. Diluted antiserum raised against human IAPP was incubated on the plate for 90 minutes at 37°C. Following washing in PBS/Tw, alkaline phosphatase conjugated anti-rabbit antisera was incubated for 90 mins. Following washing in PBS/Tw, alkaline phosphate substrate was added and colour allowed to develop for 30 mins. Optical density was read at 405nm.

Data from all samples was calculated to determine changes of IAPP concentration in the supernatant induced by the candidate substance immediately (i.e. at time zero) or after 24 h incubation. Data in Figure 1 is expressed as the proportion of non-fibrillar IAPP in the supernatant of test samples compared to control at both time points.

Candidate substances (i), (ii), (v), (vi), (ix), (x), the hydrochloride of (iii), and the sodium salt of (iv), (vii) and (viii) were found to increase the proportion of non-fibrillar IAPP in the supernatant. This effect was greater at time zero in samples incubated with (vi) and (x), but greater at time 24 h with all other candidate substances.

Samples of the centrifuged pellet at both time points were examined for changes in morphological characteristics of IAPP fibrils by electron microscopy.

Example 5

Determination of the rate of fibril formation by Thioflavine T spectroscopy

Thioflavine-T binds to proteins in β-sheet formation exhibiting a yellow fluorescence. This can be used as a sensitive assay for fibril formation under different conditions. This assay has been used in experiments to determine the effects of some candidate compounds on fibril formation.

Human IAPP was dissolved in 40% Trifuoroethanol and freeze dried into convenient sized aliquots. IAPP (1mg/ml) was prepared immediately before the measurement by dissolving in 40% HFIP in water to maintain the peptide in alpha

confirmation and soluble A stock solution of Thioflavine T (2 5mM) was prepared 7 9mg in 10ml Tris pH 7 0 and filtered (0 22 micron) Solutions were kept in dark until use Fluorescence was examined at 440nm excitation (slit 5nm), and Emission at 482nm (Slit 10nm) with stirring Twenty five microlitres of Th-T stock (final conc 62 5 µM) was added to peptide sample (8µg/ml) and made up to 1ml in the cuvette The sample was stirred for 5 min before taking a reading Measurements were made at an initial time points (5 mins from sample preparation) and at intervals over the next 4-6h after overnight incubation at room temp with and without candidate compound (vi) and a compound known to accelerate fibril formation, polyvinylsulphonate

In the thioflavine T assay, polyvinylsulphonate increased the fluorescence units (Figure 2) and compound (vi) reduced fluorescence below the level recorded for IAPP alone This reduced level was stable for up to 15 hrs Thus it appears that polyvinylsulphonate increased IAPP fibril formation and (vi) either reduced or prevented fibril formation over this time period.

Example 6

Circular Dichroic Spectroscopy

Human IAPP was prepared in 100% HFIP at 1mg/ml filtered through a 0.3µm filter, freeze dried in aliquots, resuspended in 20% HFIP and water, and filtered before analysis. The circular dichroic spectroscopy was performed in the same manner as described in Hubbard *et al* (1991) Biochem J, 275, 785-8. Samples were analysed immediately and after 24 h incubation with candidate substances i, iii, iv and x. Samples of IAPP alone (CNTL) and IAPP with candidate compound showed typical CD spectra for α-conformation at time zero. After 24 h incubation the molecular conformation of IAPP (CNTL) was converted to β-conformation. IAPP in the presence of these candidate compounds remained in α-conformation after 24 h incubation. These data indicate that with time IAPP adopts a β-conformation predicting formation of β-sheet assembly into fibrils. This is prevented by the candidate compounds. The results of the circular dichroic spectroscopy are shown in Figure 3.

Example 7

Culture of human islets

Pancreas was obtained from organ donors Islets isolated by collagenase digestion were either handpicked from the digest or purified on a ficoll gradient Islets were cultured, free floating in bacterial petrie dishes in different media all from Gibco Life Sciences, these included Ham F10, RPMI 1640, CMRL The media was supplemented with glucose (5 6, 8, 11.1 or 16.7mM), 100u/ml benzpenicillin, 0.1 mg/ml streptomycin and 10% foetal calf serum The media was changed every two days Islets were cultured under sterile conditions at 37°C in humidified air/5% Carbon dioxide for periods of 2-10 days. Fibrils formed between cultured cells were identified by electron microscopy and immunogold labelling for IAPP. Figure 4a shows an electron micrograph of isolated human islet cells immunogold labelled for IAPP The cells were cultured for 6 days in 8mM glucose and RPMI

Culture of mouse islets

These are used as a test system for determining the toxicity and effect of putative amyloid inhibitors in short term culture systems. Whereas normal mice can be used to determine toxicity of compounds added to the media, amyloid fibrils form only in murine islets isolated from transgenic mice expressing the gene for human IAPP (transgene incorporation was confirmed by PCR). These islets are isolated in a similar way to that of human islets and are handpicked from the digest and cultured in 16.7mM glucose as above. Amyloid fibrils formed within 4 days of culture and can be quantified by quantitative electron microscopy. Figure 4b shows an electron micrograph of of isolated transgenic mouse islet cells which express and secrete human IAPP. The cells were cultured for 6 days in 11.1 mM glucose and RPMI.

Example 9

Toxicity Study

Islets from transgenic mice were cultured in the presence of 50mM and 100mM of the relevant compound and survival was compared with islets cultured in the absence of the compound. Mean islet survival with both concentrations of the

compound is shown in Figure 6 (mean of all experiments with both concentrations + SD) No significant differences were seen between the control (con) and test islets at either concentration with any compound tested

Example 9

Election micrograph analysis of the effect of candidate compounds

Transgenic islets cells were cultured as described above, for 7 days and the media changed every two days At the end of the culture period the islets were fixed in 2.5% glutaraldehyde in 0 1M sodium phosphate buffer (pH 7 2) for one hour and post-fixed in 1% osmium tetroxide, and embedded in Spurr's resin (Taab Laboratories, Reading, UK) or contrast enhanced in 2% Uranyl Acetate, dehydrated in methanol and embedded in LRGold (Taab, as previous) Ultrathin sections of the islets were mounted on formvar coated nickel grids Amyloid was identified by immunogold labelling of tissue sections with an antisera raised to human IAPP 1-37, human IAPP 17-37, rat IAPP 1-37 and goat anti-rabbit gold conjugate (10nm diameter) either from Biocell, Cardiff, UK or Sigma or by use of protein A gold. Grids were examined in a JOEL electron microscrope at an excitation voltage of 80kV

Images of 3 islet sections at a low magnification were prepared. A montage of each islet was made from electron micrographs and the areas of both intra and extra cellular amyloid identified and marked. The total islet area, together with the area of intra and extra cellular amyloid was then calculated using image analysis (Kontron Image Processor). 3 separate islets were examined for each condition.

The table below shows total islet area in cultures with and without vii.

CONTROL	Extra amyloid area (μm^2)	Total islet area (μm^2)	Extra amyloid % of total
islet 1	59.39	3271 48	1 8
islet 2	281 74	4485 74	6 2
islet 3	111 09	3277 28	3 4
Average	150 74	3678 17	4.1
With vii			
islet 1	98.73	5744 23	1.9
islet 2	37.9	7360 63	0.5
islet 3	123.99	3616.76	3.4
Average	86 8	5407 21	1.6

Example 10

Morphological characteristics of IAPP fibrils formed in mixtures with candidate compounds

IAPP prepared as in Example 3 was incubated with candidate compounds for 48 h. Samples were then examined by transmission electron microscopy for the presence of fibrils. A dense network of fibrils was visible in negatively stained preparations of IAPP (1mg/ml) as can be seen in Figure 5a. Long and short unbranching fibrils were present. Samples incubated with compound (ii) contained less fibrils and those present were short and not aggregated (Figure 5b). Samples incubated with compound (vi) also contained fewer fibrils which were apparently short and long and not aggregated (Figure 5c). These data indicate that the process of IAPP fibril formation with time has been reduced by candidate compounds (ii) and (vi).

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims. The contents of all references, issued patents, and published patent applications cited throughout this application are hereby incorporated by reference.

CLAIMS

1. A method for inhibiting IAPP-associated amyloid deposits in a subject, comprising administering to said subject an effective amount of an IAPP fibril inhibiting compound, or a pharmaceutically acceptable salt thereof, such that said IAPP-associated amyloid deposits are inhibited

2 The method of claim 1 wherein said IAPP fibril inhibiting compound is of the formula



wherein k, m, t, p and q are independently 0 or 1; n is an integer from 0 to 3; C is a carbon; N is a nitrogen; W is hydrogen or an anionic group at physiological pH, Y is an anionic group at physiological pH; R^1 and R^2 are independently hydrogen, alkyl, an anionic group at physiological pH, or R^1 and R^2, taken together with the nitrogen to which they are attached, may form an unsubstituted or substituted heterocycl having from 3 to 7 atoms in the heterocyclic ring; R^3 is hydrogen, halogen, thiol or hydroxyl; R^4, R^5, and R^6 are independently hydrogen or halogen; and A is hydrogen or C_1 to C_6 alkyl; or a pharmaceutically acceptable ester, acid or salt thereof.

3. The method of claim 2, wherein said IAPP fibril inhibiting compound is selected from the group consisting of 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid; DL-2-amino-5-phosphovaleric acid; 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine; cyclohexylsulfamic acid; *O*-phospho-*L*-serine; hexafluoroglutaric acid; 8-methoxyquinoline-5-sulfonic acid; 3-amino-2-hydroxy-1-propanesulfonic acid; and 3-dimethylamino-1-propanesulfonic acid, and pharmaceutically acceptable salts thereof.

4 The method of claim 1 wherein said IAPP fibril inhibiting compound is of the formula



wherein C is a carbon, N is a nitrogen, H is a hydrogen; A^1, A^2, A^3, A^4, A^5 and A^6 are independently alkyl, O, S, or -NH; m and n (for each individual A group) are independently 0 or 1; p, q and l are independently 0, 1, or 2; R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, and each R^{14} are independently hydrogen, alkyl, alicyclyl, heterocycyl or aryl, each R^{13} is independently hydrogen, alkyl, alicyclyl. heterocycyl, aryl or an anionic group, and adjacent R groups (e.g., R^7 and R^8) may form an unsubstituted or substituted cyclic or heterocyclic ring

5. The method of claim 4 wherein said compound is 1,2,3,4-tetrahydroisoquinoline.

6. The method of claim 1, wherein said IAPP fibril inhibiting compound is administered *in vitro* or *ex vivo*.

7. The method of claim 1, wherein said subject has IAPP-associated amyloid deposits in pancreatic islets.

8. A method for inhibiting IAPP fibrillogenesis in a subject, comprising administering to said subject an effective amount of an IAPP fibril inhibiting compound, or a pharmaceutically acceptable salt thereof, such that IAPP fibrillogenesis is inhibited.

9. The method of claim 8, wherein said IAPP fibril inhibiting compound

is administered *in vitro* or ex vivo.

10 A method for reducing IAPP-associated amyloid deposits in a subject having IAPP-associated amyloid deposits, the method comprising administering to said subject an effective amount of an IAPP fibril inhibiting compound, or a pharmaceutically acceptable salt thereof, such that said IAPP-associated amyloid deposits are inhibited

11. The method of claim 10 wherein said IAPP fibril inhibiting compound is of the formula



wherein k, m, t, p and q are independently 0 or 1; n is an integer from 0 to 3; C is a carbon; N is a nitrogen; W is hydrogen or an anionic group at physiological pH; Y is an anionic group at physiological pH; R^1 and R^2 are independently hydrogen, C_1 to C_4 alkyl, an anionic group at physiological pH, or R^1 and R^2, taken together with the nitrogen to which they are attached, may form an unsubstituted or substituted heterocycle having from 3 to 7 atoms in the heterocyclic ring; R^3 is hydrogen, halogen, thiol or hydroxyl; R^4, R^5, and R^6 are independently hydrogen or halogen; and A is hydrogen or C_1 to C_6 alkyl; or a pharmaceutically acceptable ester, acid or salt thereof.

12. The method of claim 11, wherein said IAPP fibril inhibiting compound is selected from the group consisting of 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid; DL-2-amino-5-phosphovaleric acid; 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine; cyclohexylsulfamic acid; *O*-phospho-*L*-serine; hexafluoroglutaric acid; 8-methoxyquinoline-5-sulfonic acid; 3-amino-2-hydroxy-1-propanesulfonic acid; and 3-dimethylamino-1-propanesulfonic acid, and pharmaceutically acceptable salts thereof.

13 The method of claim 10 wherein said IAPP fibril inhibiting compound is of the formula



wherein C is a carbon, N is a nitrogen; H is a hydrogen; A^1, A^2, A^3, A^4, A^5 and A^6 are independently alkyl, O, S, or -NH; m and n (for each individual A group) are independently 0 or 1; p, q and l are independently 0, 1, or 2; R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, and each R^{14} are independently hydrogen, alkyl, alicyclyl, heterocycyl or aryl, each R^{13} is independently hydrogen, alkyl, alicyclyl, heterocycyl, aryl or an anionic group, and adjacent R groups (e.g., R^7 and R^8) may form an unsubstituted or substituted cyclic or heterocyclic ring.

14. The method of claim 13 wherein said compound is 1,2,3,4-tetrahydroisoquinoline.

15. The method of claim 10, wherein said IAPP fibril inhibiting compound is administered *in vitro* or *ex vivo*.

16. The method of claim 10, wherein said subject has IAPP-associated amyloid deposits in pancreatic islets.

17. A method for inhibiting amyloid deposits in a subject, comprising administering to said subject an effective amount of a compound of the formula



wherein k, m, t, p and q are independently 0 or 1, n is an integer from 0 to 3; C is a carbon; H is a hydrogen; W is hydrogen or an anionic group at physiological pH, Y is an anionic group at physiological pH, R^1 and R^2 are independently hydrogen, C_1 to C_4 alkyl, an anionic group at physiological pH, or R^1 and R^2, taken together with the nitrogen to which they are attached, may form an unsubstituted or substituted heterocycle having from 3 to 7 atoms in the heterocyclic ring; R^3 is hydrogen, halogen, thiol or hydroxyl; R^4, R^5, and R^6 are independently hydrogen or halogen; and A is hydrogen or C_1 to C_6 alkyl; or a pharmaceutically acceptable ester, acid or salt thereof, such that said amyloid deposits are inhibited.

18. The method of claim 17, wherein said IAPP fibril inhibiting compound is selected from the group consisting of 3-(3-hydroxy-1-propyl)amino-1-propanesulfonic acid; DL-2-amino-5-phosphovaleric acid; 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine; cyclohexylsulfamic acid; *O*-phospho-*L*-serine; hexafluoroglutaric acid; 8-methoxyquinoline-5-sulfonic acid; 3-amino-2-hydroxy-1-propanesulfonic acid; and 3-dimethylamino-1-propanesulfonic acid, and pharmaceutically acceptable salts thereof.

19. A method for inhibiting amyloid deposits in a subject, comprising administering to said subject an effective amount of a compound of the formula



wherein C is a carbon, N is a nitrogen, H is a hydrogen, A^1, A^2, A^3, A^4, A^5 and A^6 are independently alkyl, O, S, or -NH, m and n (for each individual A group) are independently 0 or 1; p, q and l are independently 0, 1, or 2; R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, and each R^{14} are independently hydrogen, alkyl, alicyclyl, heterocycyl or aryl, each R^{13} is independently hydrogen, alkyl, alicyclyl, heterocycyl, aryl or an anionic group, and adjacent R groups (e g., R^7 and R^8) may form an unsubstituted or substituted cyclic or heterocyclic ring.

20. The method of claim 19 wherein said compound is 1,2,3,4-tetrahydroisoquinoline.

21. An IAPP fibril inhibiting compound as defined in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, for use in inhibiting IAPP-associated amyloid deposits in a subject.

22. Process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming amyloid deposits, said process comprising contacting the cells *in vitro* with an inhibitor of amyloid deposit formation.

23. Process according to claim 22 wherein said inhibitor causes breakdown of amyloid deposits, the deposits having been formed by said cells prior

to said contacting.

24 Process according to claim 22 or claim 23 in which the cells are cultured in the presence of the inhibitor

25 Process according to any one of claims 22 to 24 wherein the inhibitor is a compound as defined in claim 2

26 Process according to any one of claims 22 to 24 wherein the inhibitor is a compound as defined in claim 4

27 Process according to any one of claims 22 to 26 wherein the inhibitor is

(i) 3-(3-hydroxy-1-propyl) amino-1- propanesulfonic acid

$HOCH_2CH_2CH_2NHCH_2CH_2CH_2SO_3H$,

(ii) DL-2-amino-5-phosphovaleric acid



(iii) 1, 2, 3, 4 tetrahydroisoquinoline



(iv) Cyclohexylsulfamic acid



(v) O-Phospho-L-serine



(vi) Hexafluoroglutaric acid



(vii) 8-methoxy quinoline-5-sulfonic acid



(viii) 4-phenyl-1- (3'-sulfopropyl)- 1, 2, 3, 6 - tetrahydropyridine



(ix) 3-amino-2-hydroxy-1- propanesulfonic acid



or

(x) 3-dimethylamino-1-propanesulfonic acid

$Me_2NCH_2CH_2CH_2SO_3H$,

or a salt thereof

28 Process according to any one of claims 22 to 27 wherein the cells are islet, liver, muscle, kidney, neuronal or stem cells

29 Process according to any one of claims 22 to 28 wherein the cells are human, primate, rodent, rabbit, ovine, porcine, feline or canine cells

30 Process according to any one of claims 22 to 29 wherein the amyloid deposits comprise islet amyloid polypeptide, Aβ peptide (involved in Alzheimer's disease), prion protein, immunoglobulin light chain, amyloid A protein, transthyretin, cystatin, β2-microglobulin, apolipoprotein A-1, gelsolin, calcitonin, atrial natriuretic factor, lysozyme variants, insulin, or fibrinogen.

31. Process according to any of claims 22 to 30 wherein the cells are islet cells and the deposits comprise human islet amyloid polypeptide.

32. A culture medium or a culture medium pre-mix which comprises an inhibitor or compound as defined in any one of claims 2, 4, 22 or 27.

33. A culture of cells in which the culture medium is as defined in claim 32.

34. A culture according to claim 33 in which the cells are islet cells.

35. *Ex vivo* cells prepared by a process according to any one of claims 22 to 31.

36. *Ex vivo* cells according to claim 35 wherein said cells are in a preparation that comprises an inhibitor or compound as defined in any one of claims 2, 4, 27 or 32.

37 *Ex vivo* cells according to claim 35 or claim 36, wherein the cells are genetically modified

38 *Ex vivo* cells according to claim 35, 36 or 37 for use in a method of treatment of the human or animal body by therapy

39 *Ex vivo* cells according to claim 38 which are islet cells for use in a method of treating diabetes

40 *Ex vivo* cells according to claim 38 for use in a method of treating type I or type II diabetes, Alzheimer's disease, a spongiform encephalopathy, primary or secondary systemic amyloidosis, familial amyloidotic polyneuropathy, senile systemic amyloidosis, hereditary cerebral amyloid angiopathy, haemodialysis-related amyloidosis, Finnish hereditary amyloidosis, medullary carcinoma of the thyroid, atrial amyloidosis, lysozyme amyloidosis, or fibrinogen α-chain amyloidosis

41. A pharmaceutical composition comprising a cell according to claim 35, 36 or 37 and a pharmaceutically acceptably carrier or diluent.

42. Use of an inhibitor as defined in any one of claims 2, 4, 22 or 27 in the manufacture of a medicament for inhibiting amyloid deposit formation by, or breaking amyloid deposits down in, a transplanted cell preparation.

43. A vessel for containing a culture of cells, which vessel is coated with an inhibitor or compound as defined in any one of claims 2, 4, 22 or 27.

44. A kit for culturing cells comprising a culture medium or culture medium pre-mix as defined in claim 32 or a vessel as defined in claim 43.

44. Use of an antibody that binds an inhibitor or compound as defined in claim 2, 4 or 27, or of a fragment of said antibody that retains the ability to bind the said inhibitor or compound, to identify a substance that can be used to prepare cells for transplantation in a process according to claim 22 or 23 .

46. Method of identifying an inhibitor that can be used to prepare cells for transplantation in a process according to claim 22 or 23, comprising contacting a

candidate substance with a mammalian cell and determining whether the candidate substance inhibits the formation of fibrils or causes the breakdown of fibrils, (i) the inhibition of formation of fibrils or (ii) the breakdown of fibrils, indicating that the substance is an inhibitor that can be used in said process

47 Method of identifying an inhibitor that can be used to prepare cells for transplantation in a process according to claim 22 or 23, comprising contacting a candidate substance with a protein capable of forming fibrils, or with a fibril, and determining whether the substance inhibits the formation of the protein into a fibril, or whether the substance causes the breakdown of the fibril, (i) inhibition of fibril formation or, (ii) the breakdown of fibrils, indicating that the substance can be used in said process

48 A method according to claim 46 or 47 wherein the mammalian cell is any of the types of cells defined in claim 28, 29 or 31, or the fibrils comprise a protein as defined in claim 30 or 31.

49 A inhibitor identified by the use or method of any one of claims 45 to 48.

50 A process, culture medium, culture medium pre-mix, culture, *ex vivo* cells, pharmaceutical composition, use, vessel or kit according to any one of claims 22 to 44 wherein the inhibitor is an inhibitor as defined in claim 49.

51. Method of inhibiting fibril formation by, or breaking fibrils down in, a transplanted cell preparation comprising administering an inhibitor or compound as defined in any one of claims 2, 4, 22, 27 or 49 to a patient who has received a transplant of cells as defined in claim 35, 36 or 37.

52. Use of a compound as defined in any one of claims 1 to 5 in the manufacture of a medicament for inhibiting IAPP-associated amyloid deposits in a subject.



Fig.1.

Fig.2.



Fig.3a.



Fig.3b.





Fig.3c.



Fig.3d.

Fig.4a.



Fig.4b.



Fig.5.





Fig.6.

#4

DECLARATION, PETITION AND POWER OF ATTORNEY FOR PATENT APPLICATION

(Check one):

☐ Declaration Submitted with Initial Filing

☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

the specification of which (check one):

☐ is attached hereto.

OR

☒ was filed on **07 July 2000** as PCT International Application Number **PCT/GB00/02623**, now U.S. Application Number **10/030,350**, filed 07 January 2002.

☐ and was amended by PCT Article 19 Amendment on _____ (if applicable),

☐ and was amended by PCT Article 34 Amendment on _____ (if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

PRIORITY CLAIM

(Check one):

☐ no such applications have been filed.

☒ such applications have been filed as follows

1) FOREIGN PRIORITY CLAIM: I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached Yes	Certified Copy Attached No
9916214.1	**GB**	**09 July 1999 (09.07.1999)**	☐	☐	☒
9916315.6	**GB**	**12 July 1999 (12.07.1999)**	☐	☐	☒

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

2) PROVISIONAL PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/142,907	**09 July 1999 (09.07.1999)**
60/142,953	**12 July 1999 (12.07.1999)**

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

3) U.S./PCT PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number *(if applicable)*

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Jeremiah Lynch	Reg. No. 17,425
Thomas V. Smurzynski	Reg. No. 24,798	David J. Rikkers	Reg. No. 43,882
Ralph A. Loren	Reg. No. 29,325	Maria C. Laccotripe	Limited Recognition
Giulio A. DeConti, Jr.	Reg. No. 31,503		Under 37 C.F.R. § 10.9(b)
Ann Lamport Hammitte	Reg. No. 34,858	Debra J. Milasincic	Reg. No. 46,931
Elizabeth A. Hanley	Reg. No. 33,505	David R. Burns	Reg. No. 46,590
Amy E. Mandragouras	Reg. No. 36,207	Sean D. Detweiler	Reg. No. 42,482
Anthony A. Laurentano	Reg. No. 38,220	Cynthia L. Kanik	Reg. No. 37,320
Kevin J. Canning	Reg. No. 35,470	Theodore R. West	Reg. No. 47,202
Jane E. Remillard	Reg. No. 38,872	Shayne Y. Huff	Reg. No. 44,784
DeAnn F. Smith	Reg. No. 36,683	Hathaway P. Russell	Reg. No. 46,488
Peter C. Lauro	Reg. No. 32,360	Daniel B. Ko	Reg. No. 47,332
Jeanne M. DiGiorgio	Reg. No. 41,710	John S. Curran	Reg. No. 50,445
Megan E. Williams	Reg. No. 43,270		

(25)

Send Correspondence to:

Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109, United States of America

Direct Telephone Calls to: (name and telephone number)

Elizabeth A. Hanley , (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00

Full name of first inventor **Anne CLARK**	
Inventor's signature Anne Clark	Date 1 Nov 2002
Residence Manor Road, Towersey, Thame, Oxon., England OX9 3QR	ENG
Citizenship GREAT BRITAIN	
Post Office Address (if different) (Same address as above)	

Full name of first inventor **Paul FRASER**	
Inventor's signature	Date
Residence 611 Windermere Ave., Toronto, Ontario M6S 3L9, CANADA	
Citizenship CANADA	
Post Office Address (if different) (Same address as above)	

Full name of first inventor **Bruce VERCHERE**	
Inventor's signature	Date
Residence 4937 Prince Edward Street, Vancouver, British Columbia V5W 2X1, CANADA	
Citizenship CANADA	
Post Office Address (if different) (Same address as above)	

Full name of first inventor **Ajay GUPTA**	
Inventor's signature	Date
Residence 255 St-Louis, Pointe-Claire, Quebec H9R 5L6, CANADA	
Citizenship CANADA	
Post Office Address (if different) (Same address as above)	

Full name of first inventor **David MIGNEAULT**	
Inventor's signature	Date
Residence 4545 Hurtubise, Laval, Quebec H7T 2T6, CANADA	
Citizenship CANADA	
Post Office Address (if different) (Same address as above)	

Full name of first inventor **Walter SZAREK**
Inventor's signature Date
Residence 165 Ontario Street, Suite 301, Kingston, Ontario K7L 2Y6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

DECLARATION, PETITION AND POWER OF ATTORNEY FOR PATENT APPLICATION

(Check one):

☐ Declaration Submitted with Initial Filing

☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

the specification of which (check one):

☐ is attached hereto.

OR

☒ was filed on **07 July 2000** as PCT International Application Number **PCT/GB00/02623**, now U.S. Application Number **10/030,350**, filed 07 January 2002.

☐ and was amended by PCT Article 19 Amendment on _____ (if applicable),

☐ and was amended by PCT Article 34 Amendment on _____ (if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

PRIORITY CLAIM

(Check one):

☐ no such applications have been filed.

☒ such applications have been filed as follows

1) FOREIGN PRIORITY CLAIM: I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached Yes	Certified Copy Attached No
9916214.1	**GB**	**09 July 1999 (09.07.1999)**	☐	☐	☒
9916315.6	**GB**	**12 July 1999 (12.07.1999)**	☐	☐	☒

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

2) PROVISIONAL PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/142,907	**09 July 1999 (09.07.1999)**
60/142,953	**12 July 1999 (12.07.1999)**

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

3) U.S./PCT PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number *(if applicable)*

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Jeremiah Lynch	Reg. No. 17,425
Thomas V. Smurzynski	Reg. No. 24,798	David J. Rikkers	Reg. No. 43,882
Ralph A. Loren	Reg. No. 29,325	Maria C. Laccotripe	Limited Recognition Under 37 C.F.R. § 10.9(b)
Giulio A. DeConti, Jr.	Reg. No. 31,503		
Ann Lamport Hammitte	Reg. No. 34,858	Debra J. Milasincic	Reg. No. 46,931
Elizabeth A. Hanley	Reg. No. 33,505	David R. Burns	Reg. No. 46,590
Amy E. Mandragouras	Reg. No. 36,207	Sean D. Detweiler	Reg. No. 42,482
Anthony A. Laurentano	Reg. No. 38,220	Cynthia L. Kanik	Reg. No. 37,320
Kevin J. Canning	Reg. No. 35,470	Theodore R. West	Reg. No. 47,202
Jane E. Remillard	Reg. No. 38,872	Shayne Y. Huff	Reg. No. 44,784
DeAnn F. Smith	Reg. No. 36,683	Hathaway P. Russell	Reg. No. 46,488
Peter C. Lauro	Reg. No. 32,360	Daniel B. Ko	Reg. No. 47,332
Jeanne M. DiGiorgio	Reg. No. 41,710	John S. Curran	Reg. No. 50,445
Megan E. Williams	Reg. No. 43,270		

Send Correspondence to:

Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109, United States of America

Direct Telephone Calls to: (name and telephone number)

Elizabeth A. Hanley , (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor **Anne CLARK**
Inventor's signature Date
Residence Manor Road, Towersey, Thame, Oxon., England OX9 3QR
Citizenship GREAT BRITAIN
Post Office Address (if different) (Same address as above)

2-00

Full name of first inventor **Paul FRASER**
Inventor's signature Date SEPT. 20.02
Residence 611 Windermere Ave., Toronto, Ontario M6S 3L9, CANADA CAX
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Bruce VERCHERE**
Inventor's signature Date
Residence 4937 Prince Edward Street, Vancouver, British Columbia V5W 2X1, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Ajay GUPTA**
Inventor's signature Date
Residence 255 St-Louis, Pointe-Claire, Quebec H9R 5L6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **David MIGNEAULT**
Inventor's signature Date
Residence 4545 Hurtubise, Laval, Quebec H7T 2T6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Walter SZAREK**
Inventor's signature Date
Residence 165 Ontario Street, Suite 301, Kingston, Ontario K7L 2Y6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

DECLARATION, PETITION AND POWER OF ATTORNEY FOR PATENT APPLICATION

(Check one):

☐ Declaration Submitted with Initial Filing

☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

the specification of which (check one):

☐ is attached hereto.

OR

☒ was filed on **07 July 2000** as PCT International Application Number **PCT/GB00/02623**, now U.S. Application Number **10/030,350**, filed 07 January 2002.

☐ and was amended by PCT Article 19 Amendment on _____ (if applicable),

☐ and was amended by PCT Article 34 Amendment on _____ (if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

PRIORITY CLAIM

(Check one):

☐ no such applications have been filed.

☒ such applications have been filed as follows

1) FOREIGN PRIORITY CLAIM: I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached Yes	Certified Copy Attached No
9916214.1	**GB**	**09 July 1999 (09.07.1999)**	☐	☐	☒
9916315.6	**GB**	**12 July 1999 (12.07.1999)**	☐	☐	☒

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

2) PROVISIONAL PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/142,907	**09 July 1999 (09.07.1999)**
60/142,953	**12 July 1999 (12.07.1999)**

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

3) U.S./PCT PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number *(if applicable)*

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Jeremiah Lynch	Reg. No. 17,425
Thomas V. Smurzynski	Reg. No. 24,798	David J. Rikkers	Reg. No. 43,882
Ralph A. Loren	Reg. No. 29,325	Maria C. Laccotripe	Limited Recognition Under 37 C.F.R. § 10.9(b)
Giulio A. DeConti, Jr.	Reg. No. 31,503		
Ann Lamport Hammitte	Reg. No. 34,858	Debra J. Milasincic	Reg. No. 46,931
Elizabeth A. Hanley	Reg. No. 33,505	David R. Burns	Reg. No. 46,590
Amy E. Mandragouras	Reg. No. 36,207	Sean D. Detweiler	Reg. No. 42,482
Anthony A. Laurentano	Reg. No. 38,220	Cynthia L. Kanik	Reg. No. 37,320
Kevin J. Canning	Reg. No. 35,470	Theodore R. West	Reg. No. 47,202
Jane E. Remillard	Reg. No. 38,872	Shayne Y. Huff	Reg. No. 44,784
DeAnn F. Smith	Reg. No. 36,683	Hathaway P. Russell	Reg. No. 46,488
Peter C. Lauro	Reg. No. 32,360	Daniel B. Ko	Reg. No. 47,332
Jeanne M. DiGiorgio	Reg. No. 41,710	John S. Curran	Reg. No. 50,445
Megan E. Williams	Reg. No. 43,270		

Send Correspondence to:

Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109, United States of America

Direct Telephone Calls to: (name and telephone number)

Elizabeth A. Hanley , (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor **Anne CLARK**
Inventor's signature Date
Residence Manor Road, Towersey, Thame, Oxon., England OX9 3QR
Citizenship GREAT BRITAIN
Post Office Address (if different) (Same address as above)

Full name of first inventor **Paul FRASER**
Inventor's signature Date
Residence 611 Windermere Ave., Toronto, Ontario M6S 3L9, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

3-00

Full name of first inventor **Bruce VERCHERE**
Inventor's signature Date 30 SEPT 02
Residence 4937 Prince Edward Street, Vancouver, British Columbia V5W 2X1, CANADA CAX
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Ajay GUPTA**
Inventor's signature Date
Residence 255 St-Louis, Pointe-Claire, Quebec H9R 5L6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **David MIGNEAULT**
Inventor's signature Date
Residence 4545 Hurtubise, Laval, Quebec H7T 2T6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Walter SZAREK**
Inventor's signature Date
Residence 165 Ontario Street, Suite 301, Kingston, Ontario K7L 2Y6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

#4

DECLARATION, PETITION AND POWER OF ATTORNEY FOR PATENT APPLICATION

(Check one):

☐ Declaration Submitted with Initial Filing

☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

the specification of which (check one):

☐ is attached hereto.

OR

☒ was filed on **07 July 2000** as PCT International Application Number **PCT/GB00/02623**, now U.S. Application Number **10/030,350**, filed 07 January 2002.

☐ and was amended by PCT Article 19 Amendment on _____ (if applicable),

☐ and was amended by PCT Article 34 Amendment on _____ (if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

PRIORITY CLAIM

(Check one):

☐ no such applications have been filed.

☒ such applications have been filed as follows

1) FOREIGN PRIORITY CLAIM: I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached Yes	Certified Copy Attached No
9916214.1	**GB**	**09 July 1999 (09.07.1999)**	☐	☐	☒
9916315.6	**GB**	**12 July 1999 (12.07.1999)**	☐	☐	☒

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

2) PROVISIONAL PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/142,907	**09 July 1999 (09.07.1999)**
60/142,953	**12 July 1999 (12.07.1999)**

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

3) U.S./PCT PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number *(if applicable)*

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Jeremiah Lynch	Reg. No. 17,425
Thomas V. Smurzynski	Reg. No. 24,798	David J. Rikkers	Reg. No. 43,882
Ralph A. Loren	Reg. No. 29,325	Maria C. Laccotripe	Limited Recognition
Giulio A. DeConti, Jr.	Reg. No. 31,503		Under 37 C.F.R. § 10.9(b)
Ann Lamport Hammitte	Reg. No. 34,858	Debra J. Milasincic	Reg. No. 46,931
Elizabeth A. Hanley	Reg. No. 33,505	David R. Burns	Reg. No. 46,590
Amy E. Mandragouras	Reg. No. 36,207	Sean D. Detweiler	Reg. No. 42,482
Anthony A. Laurentano	Reg. No. 38,220	Cynthia L. Kanik	Reg. No. 37,320
Kevin J. Canning	Reg. No. 35,470	Theodore R. West	Reg. No. 47,202
Jane E. Remillard	Reg. No. 38,872	Shayne Y. Huff	Reg. No. 44,784
DeAnn F. Smith	Reg. No. 36,683	Hathaway P. Russell	Reg. No. 46,488
Peter C. Lauro	Reg. No. 32,360	Daniel B. Ko	Reg. No. 47,332
Jeanne M. DiGiorgio	Reg. No. 41,710	John S. Curran	Reg. No. 50,445
Megan E. Williams	Reg. No. 43,270		

Send Correspondence to:

Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109, United States of America

Direct Telephone Calls to: (name and telephone number)

Elizabeth A. Hanley , (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor **Anne CLARK**
Inventor's signature Date
Residence Manor Road, Towersey, Thame, Oxon., England OX9 3QR
Citizenship GREAT BRITAIN
Post Office Address (if different) (Same address as above)

Full name of first inventor **Paul FRASER**
Inventor's signature Date
Residence 611 Windermere Ave., Toronto, Ontario M6S 3L9, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Bruce VERCHERE**
Inventor's signature Date
Residence 4937 Prince Edward Street, Vancouver, British Columbia V5W 2X1, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

4-00

Full name of first inventor **Ajay GUPTA**
Inventor's signature Ajupta Date 20-09-02
Residence 255 St-Louis, Pointe-Claire, Quebec H9R 5L6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

CA

Full name of first inventor **David MIGNEAULT**
Inventor's signature Date
Residence 4545 Hurtubise, Laval, Quebec H7T 2T6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Walter SZAREK**
Inventor's signature Date
Residence 165 Ontario Street, Suite 301, Kingston, Ontario K7L 2Y6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

DECLARATION, PETITION AND POWER OF ATTORNEY FOR PATENT APPLICATION

(Check one):

☐ Declaration Submitted with Initial Filing

☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

the specification of which (check one):

☐ is attached hereto.

OR

☒ was filed on **07 July 2000** as PCT International Application Number **PCT/GB00/02623**, now U.S. Application Number **10/030,350**, filed 07 January 2002.

☐ and was amended by PCT Article 19 Amendment on _____ (if applicable),

☐ and was amended by PCT Article 34 Amendment on _____ (if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

PRIORITY CLAIM

(Check one):

☐ no such applications have been filed.

☒ such applications have been filed as follows

1) FOREIGN PRIORITY CLAIM: I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached	
				Yes	No
9916214.1	**GB**	**09 July 1999 (09.07.1999)**	☐	☐	☒
9916315.6	**GB**	**12 July 1999 (12.07.1999)**	☐	☐	☒

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

2) PROVISIONAL PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/142,907	**09 July 1999 (09.07.1999)**
60/142,953	**12 July 1999 (12.07.1999)**

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

3) U.S./PCT PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number *(if applicable)*

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Jeremiah Lynch	Reg. No. 17,425
Thomas V. Smurzynski	Reg. No. 24,798	David J. Rikkers	Reg. No. 43,882
Ralph A. Loren	Reg. No. 29,325	Maria C. Laccotripe	Limited Recognition Under 37 C.F.R. § 10.9(b)
Giulio A. DeConti, Jr.	Reg. No. 31,503		
Ann Lamport Hammitte	Reg. No. 34,858	Debra J. Milasincic	Reg. No. 46,931
Elizabeth A. Hanley	Reg. No. 33,505	David R. Burns	Reg. No. 46,590
Amy E. Mandragouras	Reg. No. 36,207	Sean D. Detweiler	Reg. No. 42,482
Anthony A. Laurentano	Reg. No. 38,220	Cynthia L. Kanik	Reg. No. 37,320
Kevin J. Canning	Reg. No. 35,470	Theodore R. West	Reg. No. 47,202
Jane E. Remillard	Reg. No. 38,872	Shayne Y. Huff	Reg. No. 44,784
DeAnn F. Smith	Reg. No. 36,683	Hathaway P. Russell	Reg. No. 46,488
Peter C. Lauro	Reg. No. 32,360	Daniel B. Ko	Reg. No. 47,332
Jeanne M. DiGiorgio	Reg. No. 41,710	John S. Curran	Reg. No. 50,445
Megan E. Williams	Reg. No. 43,270		

Send Correspondence to:

Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109, United States of America

Direct Telephone Calls to: (name and telephone number)

Elizabeth A. Hanley , (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor **Anne CLARK**
Inventor's signature Date
Residence Manor Road, Towersey, Thame, Oxon., England OX9 3QR
Citizenship GREAT BRITAIN
Post Office Address (if different) (Same address as above)

Full name of first inventor **Paul FRASER**
Inventor's signature Date
Residence 611 Windermere Ave., Toronto, Ontario M6S 3L9, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Bruce VERCHERE**
Inventor's signature Date
Residence 4937 Prince Edward Street, Vancouver, British Columbia V5W 2X1, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Ajay GUPTA**
Inventor's signature Date
Residence 255 St-Louis, Pointe-Claire, Quebec H9R 5L6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

5-a

Full name of first inventor **David MIGNEAULT**
Inventor's signature David Migneault Date September 23, 2002
Residence 4545 Hurtubise, Laval, Quebec H7T 2T6, CANADA CAN
Citizenship CANADA
Post Office Address (if different) (Same address as above)

Full name of first inventor **Walter SZAREK**
Inventor's signature Date
Residence 165 Ontario Street, Suite 301, Kingston, Ontario K7L 2Y6, CANADA
Citizenship CANADA
Post Office Address (if different) (Same address as above)

DECLARATION, PETITION AND POWER OF ATTORNEY FOR PATENT APPLICATION

(Check one):

☐ Declaration Submitted with Initial Filing

☒ Declaration Submitted after Initial Filing

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION

the specification of which (check one):

☐ is attached hereto.

OR

☒ was filed on **07 July 2000** as PCT International Application Number **PCT/GB00/02623**, now U.S. Application Number **10/030,350**, filed 07 January 2002.

☐ and was amended by PCT Article 19 Amendment on _____ (if applicable),

☐ and was amended by PCT Article 34 Amendment on _____ (if applicable).

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

[redacted]

PRIORITY CLAIM

(Check one):

☐ no such applications have been filed.

☒ such applications have been filed as follows

1) FOREIGN PRIORITY CLAIM: I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (dd/mm/yyyy)	Priority Not Claimed	Certified Copy Attached	
				Yes	No
9916214.1	**GB**	**09 July 1999 (09.07.1999)**	☐	☐	☒
9916315.6	**GB**	**12 July 1999 (12.07.1999)**	☐	☐	☒

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

2) PROVISIONAL PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Provisional Application Number(s)	Filing Date (dd/mm/yyyy)
60/142,907	**09 July 1999 (09.07.1999)**
60/142,953	**12 July 1999 (12.07.1999)**

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

3) U.S./PCT PRIORITY CLAIM: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (dd/mm/yyyy)	Parent Patent Number *(if applicable)*

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Jeremiah Lynch	Reg. No. 17,425
Thomas V. Smurzynski	Reg. No. 24,798	David J. Rikkers	Reg. No. 43,882
Ralph A. Loren	Reg. No. 29,325	Maria C. Laccotripe	Limited Recognition Under 37 C.F.R. § 10.9(b)
Giulio A. DeConti, Jr.	Reg. No. 31,503		
Ann Lamport Hammitte	Reg. No. 34,858	Debra J. Milasincic	Reg. No. 46,931
Elizabeth A. Hanley	Reg. No. 33,505	David R. Burns	Reg. No. 46,590
Amy E. Mandragouras	Reg. No. 36,207	Sean D. Detweiler	Reg. No. 42,482
Anthony A. Laurentano	Reg. No. 38,220	Cynthia L. Kanik	Reg. No. 37,320
Kevin J. Canning	Reg. No. 35,470	Theodore R. West	Reg. No. 47,202
Jane E. Remillard	Reg. No. 38,872	Shayne Y. Huff	Reg. No. 44,784
DeAnn F. Smith	Reg. No. 36,683	Hathaway P. Russell	Reg. No. 46,488
Peter C. Lauro	Reg. No. 32,360	Daniel B. Ko	Reg. No. 47,332
Jeanne M. DiGiorgio	Reg. No. 41,710	John S. Curran	Reg. No. 50,445
Megan E. Williams	Reg. No. 43,270		

Send Correspondence to:

Elizabeth A. Hanley, Lahive & Cockfield, LLP, 28 State Street, Boston, Massachusetts 02109, United States of America

Direct Telephone Calls to: (name and telephone number)

Elizabeth A. Hanley , (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor **Anne CLARK**
Inventor's signature Date
Residence Manor Road, Towersey, Thame, Oxon., England OX9 3QR
Citizenship GREAT BRITAIN
Post Office Address (if different) (Same address as above)

Full name of first inventor **Paul FRASER**	
Inventor's signature	Date
Residence 611 Windermere Ave., Toronto, Ontario M6S 3L9, CANADA	
Citizenship CANADA	
Post Office Address (if different) (Same address as above)	

Full name of first inventor **Bruce VERCHERE**	
Inventor's signature	Date
Residence 4937 Prince Edward Street, Vancouver, British Columbia V5W 2X1, CANADA	
Citizenship CANADA	
Post Office Address (if different) (Same address as above)	

Full name of first inventor **Ajay GUPTA**	
Inventor's signature	Date
Residence 255 St-Louis, Pointe-Claire, Quebec H9R 5L6, CANADA	
Citizenship CANADA	
Post Office Address (if different) (Same address as above)	

Full name of first inventor **David MIGNEAULT**	
Inventor's signature	Date
Residence 4545 Hurtubise, Laval, Quebec H7T 2T6, CANADA	
Citizenship CANADA	
Post Office Address (if different) (Same address as above)	

6-w

Full name of first inventor **Walter SZAREK**
Inventor's signature W. A. Szarek — Date: August 8, 2002
Residence 165 Ontario Street, Suite 301, Kingston, Ontario K7L 2Y6, CANADA CA X
Citizenship CANADA
Post Office Address (if different) (Same address as above)